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ABSTRACT
Recombinant protein therapeutics are widely used to treat life-threatening
diseases including cancer. Chinese hamster ovary (CHO) cells have been used for over 25
years in the biopharmaceutical industry to produce recombinant protein therapeutics,
where CHO cells produce almost one in three of the manufactured recombinant protein
therapeutics. CHO cell lines are the preferred host for protein expression due to their
ability to produce human-compatible protein glycosylation, mediate protein folding, ease
of culturing in large-scale bioreactors and protein expression stability. However, the
protein titers are only 5-10 g/L, leading to high market prices of the biopharmaceuticals.
Understanding of CHO cells in the bioprocessing industry has heavily relied on empirical
characterization with a limited knowledge of the molecular dynamics. Transcriptomics is
one such medium through which cellular mechanisms could be better understood by
measuring gene expression. Moreover, with the recent establishment of both Chinese
hamster and CHO-K1 cell line genome assemblies, it is now possible to leverage these
genomic resources to better understand and further improve CHO cell bioprocessing. The
information obtained from the comprehensive transcriptome analysis can be leveraged to
engineer CHO cells with desired phenotypes including high protein titers and used to
control the bioreactor environment to reduce waste production. This dissertation work
harnessed the capabilities of next-generation transcriptomic technique, RNA-seq, to
quantify the gene expression changes in CHO cells under several industrially relevant
treatments including changes due to the adaptation of CHO cells to serum-free media,
low temperature, low pH and medium glucose concentration.
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Like most mammalian cells, parental CHO cell lines are grown as adherent cells
in serum supplemented medium. Due to regulatory issues about the use of serum, CHO
cells are grown as suspension cells in serum-free medium in large industrial bioreactors.
However, CHO cell lines have to be adapted to serum-free medium, prior to large-scale
cultivation. Adaptation of CHO cells to serum-free medium is a tedious, time-consuming
process and can lead to complications such as cell cycle arrest and cell death in CHO
cells undergoing adaptation process. In order to characterize the serum-free adaptation
process, we adapted a parental cell line, CHO DHFR-, and a recombinant cell line, rCHO
DP-12, from a serum-containing medium to a serum-free, protein-free chemically defined
medium. The recombinant rCHO DP-12 cell line adapted to the serum-free media in
about two months, while the CHO DHFR- cells only partially adapted to serum-free
medium. For transcriptome analysis, RNA samples from the two cell lines were taken
from different serum-free adaptation stages. The transcriptome analysis was used to
evaluate the impact of serum-free medium adaptation process on glycosylation, cell cycle
and apoptosis related genes. Additionally, the gene expression differences between the
recombinant and non-recombinant CHO cell lines during the adaptation process were
investigated to address the varying adaptation behavior among it.
Often times in the biopharmaceutical industry, culture longevity and protein
productivity are improved by shifting the cells to a lower process temperature.
Alternatively, CHO cells cultured at a lower pH than typical pH values have been
observed to improve cell viability, lower waste production (such as lactate) and enhance
recombinant protein yield. Unfortunately, the impact of lower culture temperature and pH
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is highly cell line and recombinant protein specific. To understand the impact of low
temperature (33°C) and low pH on CHO cell transcriptome, RNA samples from two
CHO cell lines – a non-recombinant cell line CHO K1-PF and a recombinant cell line
CHO DP-12 at different conditions were harvested and sequenced. However, the impact
of culture pH on CHO cell transcriptome was found to be minimal in this work.
Differential gene expression analysis identified 3,186 genes significantly impacted by
temperature in both CHO cell lines. Genes related to DNA replication, DNA repair and
translation were sensitive to temperature and had lower expression at 33°C. Additionally,
glycosylation related genes such as Slc35d1 and Slc35d2, which are involved in the
transport of nucleotide sugars, were found to have higher expression at lower
temperatures.
For most mammalian cell lines, glucose serves as the primary carbon
source required for growth and maintenance. Glucose metabolism is also central to
several key intermediates for the synthesis of cellular components such as lipids, sugar
chains and nucleic acids are generated during glycolysis. However, incomplete oxidation
of glucose can lead to lactate production and inefficient low energy. Typically,
mammalian cell culture media contain glucose concentrations ranging from 25 mM to 35
mM (~4.5 g/L to 6.5 g/L). Glucose concentrations above 10 mM are analogous to
diabetic levels of glucose in humans, suggesting that the mammalian cells are cultivated
in excess glucose. Alternatively, maintaining low glucose concentrations (~ 5mM) has
been attempted to reduce the glucose intake by mammalian cells. The effects of
extracellular glucose concentration (30 mM or 10 mM) on the transcriptome of rCHO
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DP-12 cells producing monoclonal antibody were investigated. Only 575 genes were
identified as significantly different (FDR ≤ 0.01). Moreover, gene expression analysis
revealed that no notable changes in glycolysis, TCA cycle or glycosylation genes were
observed in CHO cell cultured under different glucose concentrations. These expression
studies indicated that low glucose concentration batch medium for fed-batch CHO cell
cultures has potential to improve processes by reducing waste accumulation without
impacting process related genes.
Overall, the transcriptome studies exploited the availability of recent
Chinese hamster genome data to gain insights into the impact of industrially relevant
treatments on CHO cells. The data obtained from these studies could be utilized to dictate
improvements in cell line engineering and media development to further improve
production processes.
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CHAPTER 1
INTRODUCTION

1.1 MOTIVATION
In the last twenty years, more than 230 biopharmaceuticals (also called biologics)
have been approved by the United States Food and Drug Administration (FDA);
furthermore there are over 200 biopharmaceuticals currently in development (Carter
2011; Kantardjieff and Zhou 2013; Walsh 2010). These biopharmaceuticals are used to
treat debilitating diseases such as cancer, cardiovascular diseases, and HIV/AIDS (Datta,
et al. 2013; Walsh 2010). It has been estimated that the biologics on market have
benefitted more than 250 million people globally (Walsh 2003). With the present
availability of biopharmaceuticals in markets and a greater number in clinical
development stages, the revenue generated is expected to be around $180 billion in the
year 2016 (Bandaranayake and Almo 2013; Batra, Anurag S Rathore Jyoti 2016; Butler
and Meneses-Acosta 2012; Carter 2011). Despite its ability to treat life-threatening
diseases, one of the major issues associated with biopharmaceuticals are the very high
treatment costs. For example, a treatment using a recombinant monoclonal antibody can
cost over $100,000/year per patient. These high treatment costs have resulted in questions
about the affordability of such treatments (Malik 2009). The high costs of these
biopharmaceutical drugs have been partially attributed to the low amounts of protein
produced by Chinese hamster ovary (CHO) cell cultures and the long culture times.
Therefore, improving protein production levels in CHO cells is essential and highly
relevant to bring down biopharmaceutical costs. In the last 30 years of the
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biopharmaceutical industry, the improvements in CHO cell culture have been largely
driven through empirical efforts; however, a more fundamental understanding of the
bottlenecks in CHO cell bioprocessing is required for further advances.
Recently, genome sequences of Chinese hamster and Chinese hamster ovary cell
lines were established (Brinkrolf, et al. 2013; Lewis, et al. 2013; Xu, et al. 2011). The
newly available genomic resources presents a novel range of opportunities to delve into a
deeper understanding of Chinese hamster ovary cell lines, which was not available
previously. These genomic data can additionally support and improve other ‘omics based
techniques including transcriptomics. The understanding of the CHO cell gene expression
under industrially relevant environmental conditions that are known to alter the
productivity and product quality will facilitate better cellular level understanding that
could be used to design/optimize improved CHO cell culture processes. Additionally, the
findings could direct the engineering of CHO cell lines with favorable characteristics
such as consistent glycosylation and low waste metabolite production. The data obtained
in these studies will add to the current understanding of CHO cell responses and be a
valuable resource to the CHO cell community.
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1.2 ORGANIZATION
This dissertation is divided into six chapters. Chapter One outlines the motivation
of for this dissertation. In Chapter Two, the literature of key topics related to this work
has been reviewed. The history and importance of CHO cell lines, and transcriptome
studies related to CHO cell lines have been discussed. Additionally, literature review
related to serum-free medium adaptation, temperature and pH effects, and the impact of
glucose with respect to CHO cell cultures are presented. The chapters Three, Four and
Five present the main studies of this dissertation. Chapter Three describes the
transcriptome analysis of the CHO cells undergoing serum-free medium adaptation
process. Chapter Four describes the effects of temperature and pH on the CHO cell
transcriptome. Chapter Five discusses the impact of glucose on gene expression levels in
recombinant CHO cells. Finally, Chapter Six discusses future directions for this work.
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CHAPTER TWO
LITERATURE REVIEW

2.1 Chinese Hamster Ovary Cells
Chinese hamsters are a part of Cricetidae family and Cricetulus genus, originally
from deserts of China and Mongolia. Chinese hamsters have been long used as laboratory
models to investigate radiation cytogenetics, hereditary diseases and tissue cultures
(Jayapal, et al. 2007; Yerganian 1972; Yerganian 1985). In the late 1950s, Dr. Theodore
Puck established CHO cells from an ovary biopsy of a female Chinese hamster while
researching somatic cell genetics (Tjio and Puck 1958). Since the isolation of the first
CHO cell line, several CHO cell variants have been created through various selection and
mutation methods (Flintoff, et al. 1976; Kao and Puck 1968; Puck, et al. 1958; Tjio and
Puck 1958; Urlaub, et al. 1983; Urlaub and Chasin 1980), of which, several are major
biopharmaceutical cell line used in the production of recombinant therapeutic proteins
(Figure 1). Three different CHO cell lines were used in the following dissertation work–
a recombinant CHO cell line (rCHO DP-12 that produces an IgG against Interleukin-8)
and two non-recombinant CHO cell lines (CHO DHFR-/CHO DUXB11 and CHO K1PF). CHO DHFR- is the parental host cell line of the rCHO DP-12 cells and CHO-K1
Protein Free is the protein-free, serum-free medium adapted version of the ancestral CHO
K1 cell line.
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Figure 2.1: Lineage of CHO cell lines since its isolation in 1957. Green shaded boxes
represent the CHO cell lines used in this dissertation work. Draft genome sequences are
only available for Chinese hamster and CHO-K1 as of April 2016, as denoted by *.
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The extensive use of CHO cell lines in the biopharmaceutical industry has been
attributed to advantages such as being a well established expression system, ability to
produce human-compatible proteins, can be scaled to large-scale processes, and being
safe hosts for therapeutic protein production (Datta, et al. 2013; Jayapal, et al. 2007; Kim,
et al. 2012). One of the industrially relevant CHO cell line, CHO DUKXB11 (CHO
DXB11/CHO DHFR-), harbored the inactivated dihydrofolate reductase (DHFR) gene,
which was critical for its use in industrial therapeutic protein production (Jayapal, et al.
2007; Urlaub, et al. 1983; Urlaub and Chasin 1980; Wuest, et al. 2012). The DHFR
enzyme is required for the synthesis of the key amino acids such as hypoxanthine and
thymidine and CHO cells lacking the gene (DHFR-) require the supplementation of these
amino acids in the medium. This deficiency was exploited to develop a selection system
for recombinant CHO cells (Jayapal, et al. 2007; Wuest, et al. 2012). Furthermore, this
system allowed the amplification of the recombinant genes through the addition of
methotrexate (MTX), an inhibitor of DHFR activity. Another CHO cell selection system
utilizes glutamine synthetase (GS) as a selection marker (Blochberger, et al. 1997). It is
these selection and amplification systems that have allowed for easy manipulation and
expression of recombinant genes in CHO cells. The other major advantage of using CHO
cells over other rodent cell lines is in its ability to produce proteins with humancompatible glycosylation. In fact in the transcriptomic study of CHO K1 cell line, it was
observed that several genes coding for glycan structures, such as bisecting Nacetylglucosamine, 1,3-galactosyltrasnferase, and N-glycolyneuramic acid, that could
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potentially elicit immunogenic response in humans, were not expressed in CHO cells,
despite being found in the CHO genome (Harcum 2005; Xu, et al. 2011).
In the last few decades, CHO cell protein productivities have increased from ~
100 mg/L in the initial processes commissioned to about 5-10 g/L in the current processes
(Datta, et al. 2013; Jayapal, et al. 2007; Kim, et al. 2012). These improvements were
made possible through advances in screening and cell line development, media
optimization, process control improvements and by employing fed-batch processes.
However, the productivities are 10-100 fold lower than what can be achieved using
microbial host systems (Jayapal, et al. 2007). Additional bottlenecks include
accumulation of waste product, inconsistent glycosylation and low cell densities
(Bandaranayake and Almo 2013; Datta, et al. 2013; Wuest, et al. 2012). These limitations
primarily stem from inadequate understanding of CHO cells at cellular and molecular
level. The recent establishment of parental CHO-K1 and Chinese hamster reference
genome has opened up a new avenue for understanding CHO cells, which was not
previously possible (Lewis, et al. 2013; Xu, et al. 2011). These genomic resources will
provide support and improve other ‘omics technologies such as transcriptomics,
metabolomics and proteomics. An integrated approach of these techniques is expected to
drive next-generation CHO cell bioprocessing through an increased cellular level
understanding of these cells.
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2.2 Transcriptomics
For an increased system level understanding of CHO cells, the use of ‘omicsbased technologies has become essential (Datta, et al. 2013; Laux 2014; Wright and Estes
2014; Wuest, et al. 2012). ‘Omics is a broad discipline of science that analyzes the
interaction networks of genes, proteins and metabolic enzymes (Datta, et al. 2013; Laux
2014; Wright and Estes 2014). Specifically, transcriptomic analysis measures the
messenger RNA content within a cell at a given time (Fu, et al. 2009; Marioni, et al.
2008; Wang, et al. 2009). As transcriptome technologies have improved, greater fractions
of the mRNA within a cell have become measureable (Wang, et al. 2009; Wuest, et al.
2012). Studying the transcriptome is essential to understand genome functioning and
comparative transcriptome analyses have been widely implemented to establish
relationships between gene expression and its environmental conditions in several
different organisms. To quantify and analyze the transcriptome of an organism,
technologies have been evolved from northern blots and real-time quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR) to DNA microarrays and RNA
sequencing (RNA-seq) (Wang, et al. 2009; Wuest, et al. 2012).
In northern blots or qRT-PCR, a known mRNA sequence is amplified prior to
measuring the gene expression (Wuest, et al. 2012). In contrast, DNA microarrays have
the advantage of simultaneously probing thousands of genes hybridized on a chip. DNA
microarray technology is one of the most powerful and widely used tools for
transcriptome studies (Kantardjieff, et al. 2010; Klausing, et al. 2011). A newer
alternative method for transcriptome analysis is RNA-seq, a high-throughput sequencing
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method that directly and simultaneously sequences complementary DNA strands
producing millions of short sequence reads (30-400 bp) (Fu, et al. 2009; Marioni, et al.
2008; Mortazavi, et al. 2008). RNA-seq, unlike hybridization-based approaches such as
DNA microarray, is not limited to detecting transcripts that correspond to existing
genomic sequence (Marioni, et al. 2008; Wang, et al. 2009). RNA-Seq also provides
complete and contiguous sequences that do not require a prior annotated sequence (Fu, et
al. 2009; Mortazavi, et al. 2008). This is particularly useful for non-model organisms for
which the reference genome is absent. Additionally, RNA-seq has minimal background
noise, enabling it to detect genes with low expression, and does not have an upper limit of
detection (Fu, et al. 2009; Wang, et al. 2009). Consequently, it has a wider detection
range in comparison to DNA microarrays. Several studies that compared the gene
expression results of RNA-seq and DNA microarrays concluded that RNA-seq data was
highly reproducible and more consistent, over DNA microarrays, with the results of
parallel quantitative methods like proteomics and qRT-PCR (Fu, et al. 2009; Marioni, et
al. 2008). Despite the advantages, RNA-seq has been used sparingly due to high cost
associated with it and the tools for RNA-seq data analysis and statistical analysis are still
being refined (Fang, et al. 2012; Oshlack, et al. 2010; Rahmatallah, et al. 2014; Wang, et
al. 2009). Confounding the transition from DNA microarray to RNA-seq analysis is a
fundamental difference between the types of results obtained. RNA-seq provides discrete
counts for gene expression observed in a sample, while DNA microarrays provides
continuous intensity data representing hybridization with the target sequence (Fang, et al.
2012). The statistical analysis of discreet data requires the use of negative binomial
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distribution to model the mean-variance relationship, as opposed to the log-normal
distribution used for DNA microarray based data (Anders, et al. 2013; Oshlack, et al.
2010; Robinson and Smyth 2008; Robinson, et al. 2010; Oshlack and Wakefield 2009).
Prior to the presence of CHO genome sequence, northern blots and qRT-PCR
were widely used to assess the CHO cell gene expression under several bioprocessing
conditions such as hyperosmolarity, ammonia buildup, as well as study the behavior of
glycosylation genes in a bioreactor (Chen and Harcum 2006; Jiang and Sharfstein 2008;
Wong, et al. 2010). However, northern blots and qRT-PCR are tedious due to the geneby-gene analysis and tend to be expensive per gene examined in comparison to
microarrays and RNA-Seq (Wuest, et al. 2012). DNA microarrays provide a relative
quantitative measurement of the transcript and has been used most extensively for
comparative transcriptome analysis. Initial transcriptome studies of CHO cell responses
under different cell culture conditions were assessed by incomplete CHO DNA
microarrays and non-CHO-derived cross-species (rat or mouse) DNA microarrays due to
unavailability of sufficient sequence information (Baik, et al. 2006; De Leon Gatti, et al.
2007; Yee, et al. 2008). For example, comparative transcriptome analyses using CHO
DNA microarrays have been performed under productivity enhancing conditions such as
low temperature, high osmotic conditions and in the presence of sodium butyrate
(Kantardjieff, et al. 2009; Klausing, et al. 2011; Yee, et al. 2009). However, DNA
microarray has several drawbacks such as poor detection of low gene expression levels,
cross-hybridization between similar genes, limited number of genes that can be
hybridized on the microarray and inability to detect genes not included on the microarray.
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Additionally studies have demonstrated the inefficiency of results generated by crossspecies microarray hybridization (Ernst, et al. 2006; Yee, et al. 2008). RNA-seq has been
used in limited but impactful CHO transcriptome studies. In the publication of the draft
CHO-K1 genome sequence, Xu et al. (2011) used RNA-seq to assess the transcriptome of
CHO-K1 cells, grown in a serum-supplemented medium, to detect expression of over
24,000 genes. One key feature of the transcriptome analysis was that several viral
receptor genes were present in the genome but expression of these genes was not detected
by RNA-seq. This was important in explaining the viral-resistance characteristic of CHO
cell lines (Xu, et al. 2011). More recently, several studies have utilized RNA-Seq to
investigate clonal stability and enhancers of protein productivity in CHO cell lines
(Konitzer 2015, Orellana 2015, Li 2016, Veith 2016).
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2.3 CHO Bioprocessing Studies
Culture environmental has been well documented to influence the CHO cell
behavior (Baik, et al. 2011; Borys, et al. 1993; Borys, et al. 1994; Furukawa and Ohsuye
1998). Studies have observed that alterations in pH, media composition, temperature and
dissolved oxygen directly affect CHO cell physiology, which results in growth,
metabolism, protein yield and protein quality changes. For example, under mild
hypothermic culture conditions CHO cells often have enhanced specific protein
productivity (Kaufmann, et al. 1999; Yoon, et al. 2003b; Yoon, et al. 2003b; Yoon, et al.
2005). The understanding of the impact of key environmental factors on CHO cells is
critical to direct improvements in CHO cell bioprocessing. Often, the environmental
parameters exert control on CHO cells at cellular and molecular levels including the gene
expression/transcriptome (Chen and Harcum 2006; Kantardjieff, et al. 2010; Lee, et al.
2014; Yee, et al. 2009). In this dissertation, CHO cell gene expression was characterized
using RNA-seq during serum-free medium adaptation process, in addition to other culture
parameters such as temperature, pH and glucose levels. The following section discusses
CHO literature studies specific to serum-free medium adaptation process, culture
temperature, culture pH, and glucose concentrations.

2.3.1 Serum-free medium adaptation in CHO cells
Mammalian cell culture media have been developed and refined extensively for
over sixty years to improve cell growth and/or productivity (Freshney 2005; Ozturk and
Hu 2005). To support mammalian cell growth, it is common practice to supplement basal
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cell culture medium with 10% serum (Ozturk and Hu 2005). Serum is the supernatant of
clotted blood and is different from plasma, in that, it does not contain clotting factors.
Serum is a complex mixture of attachment factors, growth factors, vitamins, and
micronutrients. Fetal bovine serum (FBS) is the preferred additive over other animal sera
due to its purity, ease of storage and growth factor content (Even, et al. 2006). However,
animal sera, including FBS, can be a potential source of contaminants such as prions and
viruses (Costa, et al. 2013; Gstraunthaler 2003; Rodrigues, et al. 2013; Schröder, et al.
2004; Sinacore, et al. 2000). These potential contaminants pose regulatory concerns
especially when the cell culture products are used for therapeutic purposes in humans.
Additional concerns over the use of animal sera include batch variation, components
interfering with downstream purification steps, and its undefined nature, which can
complicate and cause inconsistency in CHO cell culture. Industrially, for aforementioned
reasons, CHO cells are preferred to be cultured in chemically defined serum-free
formulations (Gstraunthaler 2003; Jaluria, et al. 2008; Rasmussen, et al. 1998; Rodrigues,
et al. 2013; Zander and Bemark 2008).
Since CHO cells are traditionally grown in serum containing medium, they need
to be adapted to grow in serum-free medium. However, the adaptation process is timeconsuming, tedious and not straightforward (Baik, et al. 2011; Rodrigues, et al. 2013;
Schröder, et al. 2004; Sinacore, et al. 2000). To minimize the effects of serum
withdrawal, CHO cells are normally adapted to serum-free medium by gradually
lowering serum concentrations in a step-wise manner over several weeks. Sinacore et al.
(2000) described a three-step protocol to adapt mammalian cells, in particular CHO cells,
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to serum-free and high-density suspension cultures (Sinacore, et al. 2000). Despite this
protocol, many research groups still have difficulties adapting CHO cells to serum-free
medium as this process results in growth declination, disturbed cell cycle progression,
and activation of apoptosis pathways (Sinacore, et al. 2000). Serum removal has also
been reported to impact protein productivity and protein glycosylation quality (Costa, et
al. 2013; Gawlitzek, et al. 1995; LeFloch, et al. 2006; Watson, et al. 1994). Figure 2.2
shows the timeline of the adaptation process for CHO cells by several research groups,
which highlights the long time required. Commonly, the serum-free adaptation process
for a recombinant CHO cell lines are shorter than for non-recombinant CHO cell lines as
shown by shorter timelines of rGS-CHO and rCHO in comparison to the adaptation
timelines of non-recombinant CHO DUXB11 and CHO-K1.
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Figure 2.2: Serum-free medium adaptation timelines of several CHO cell lines by
different research groups. DUKX and DXB11 (both also known as CHO DUKXB11,
CHO DHFR-) and CHO K1 are non-recombinant cell lines, whereas rCHO and rGS-CHO
represent the recombinant cell lines.
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From an ‘omics perspective, only few studies are available in literature that have
examine the serum-free adaptation process. For instance, a recombinant CHO cell
proteome based study identified six proteins, including heat shock proteins and
nucleotide de-novo synthesis proteins, with higher expression in cells adapted to serumfree medium (Baik, et al. 2011). A study that used DNA microarray to study the serumfree medium adaptation of the human lymphoma cell line, observed higher gene
expression for cell division and central metabolism genes, and lower gene expression in
apoptosis genes (Zander and Bemark 2008). Interestingly, in the human lymphoma study,
genes related to signal transduction and cell adhesion were returned to pre-adaptation
levels once transferred to a serum containing medium, indicating these genes were
directly influenced by serum. In a different study using human embryonic kidney (HEK)
cells, DNA microarrays identified early growth response1 (EGR1) and growth arrest
specific 6 (GAS6) to have higher expression in serum-free medium adapted cells (Jaluria,
et al. 2008). Jaluria et al. (2006) subsequently overexpressed EGR1 and GAS6 genes in
non-adapted HEK cells and observed improvements in growth rates and cell viabilities
during the serum-free medium adaptation process (Jaluria, et al. 2008).

2.3.2 Temperature studies
Temperature is one of the most critical and carefully monitored environmental
factors in mammalian cell culture. CHO cells are typically cultured at a temperature of
37°C, to mimic the Chinese hamster physiological temperature (Yoon, et al. 2003a).
However, low temperature cultivation has been widely used as a strategy to improve
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critical mammalian cell culture performance parameters such as cell viability, protein
productivity and product quality (Moore, et al. 1997; Kaufmann, et al. 1999; Yoon, et al.
2003b; Kou, et al. 2011; Fogolı́n, et al. 2004; Fox, et al. 2004). Beneficial effects of low
culture temperature for CHO cells have been observed around 33°C, where temperatures
below 33°C have been observed to have detrimental effects on cell growth. For example,
when CHO cells producing erythropoietin (EPO) were cultured at 30°C, improvements in
protein productivity were negated by poor cell growth (Yoon, et al. 2003a; Yoon, et al.
2005; Yoon, et al. 2006a). Low temperature cultivation of CHO cells has been utilized to
delay the onset of apoptosis in order to extend the production period (Al‐Fageeh, et al.
2006; Fogolı́n, et al. 2004; Kaufmann, et al. 1999; Moore, et al. 1997; Trummer, et al.
2006; Yoon, et al. 2006b). Moore et al. (1997) observed that temperature shift from 37°C
to 30°C in CHO cells resulted in a four-day delay in the onset of apoptosis, possibly due
to cell growth arrest observed in up to 87% of the cells (Moore, et al. 1997). Additionally,
CHO cells cultivated under low temperatures experience lower glucose consumption and
lactate production rate, lower ATP consumption, and higher shear resistance (Al‐
Fageeh, et al. 2006; Masterton and Smales 2014)
The impact of low temperature cultivation on CHO cell protein productivity,
however, is not consistent across all cell lines. Low temperature cultivation of several
CHO cells expressing EPO, C-terminal α-amidating enzyme and tissue plasminogen
activator (tPA), have resulted in increased specific protein productivity (Furukawa and
Ohsuye 1998; Kaufmann, et al. 1999; Yoon, et al. 2003b). Several studies have linked the
improvements in protein productivity towards stability increase in recombinant mRNA
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and its improved stability at low temperatures (Fox, et al. 2004; Masterton and Smales
2014; Yoon, et al. 2003a). Despite the decrease in global protein translation, the
increased mRNA levels are suggested to compensate for it, leading to the occurrence of
enhanced protein synthesis. Additionally, the decrease in global translation may result in
‘less competition’ of the recombinant mRNAs with the endogenous mRNAs for cellular
translational machinery in the ribosome. In contrast, decreased or no change in specific
protein productivity have been observed during low temperature cultivation of
recombinant CHO cells and other mammalian cell lines (Barnabé and Butler 1994;
Sureshkumar and Mutharasan 1991; Yoon, et al. 2003a). The variability of low
temperature effect on specific protein productivity was also observed between two
different recombinant proteins produced by same host cell lines and driven by same
promoters (Yoon, et al. 2003a; Yoon, et al. 2003b). Additionally, the cell-specific impact
of low temperature was documented when 12 parental clones and their corresponding
amplified clones did not exhibit similar patterns in protein productivity improvements
(Yoon, et al. 2006a). These literature studies suggest that the effect of low temperature on
protein productivity improvements is highly cell line and product specific. The
differences in protein productivities may arise due to differences in metabolite utilization,
cell growth and recombinant mRNA expression levels (Marchant, et al. 2008; Masterton
and Smales 2014).
Nishiyama et al. (1997) reported the evidence of molecular changes in
mammalian cells cultured under low temperatures through the discovery of cold
inducible RNA-binding protein (CIRP) in mouse fibroblast cells. Expression of CIRP at
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low temperature is related to growth suppression and cell growth arrest (Al

Fageeh, et

al. 2006; Masterton and Smales 2014). A genome wide expression analysis of low
temperature effect on mouse myeloma cells revealed deregulation of genes involved in
several signaling and metabolic pathways including apoptosis, death receptor, glycolysis,
and pentose phosphate pathway. Kantardjieff et al. (2010) utilized a proprietary DNA
microarray to understand improved productivity under low temperature and butyrate
treatment (Kantardjieff, et al. 2009). Cell cycle and growth factor related genes were
down regulated while extracellular matrix and fatty acid metabolism genes were up
regulated. Unfortunately, the use of proprietary DNA microarray in this study makes it
difficult to confirm these findings. A comprehensive transcriptome analysis will be
crucial in understanding how the cellular mechanisms are coordinated upon the impact of
low temperature and why recombinant protein productivity is selectively enhanced in
some but not all CHO cells. The improved understanding can be utilized to engineer
CHO cells lines with characteristics of higher productivity and viability usually observed
at low temperatures, while cultivating CHO cells at 37°C, the optimal growth
temperature.

2.3.3 pH studies
Similar to temperature, pH is a critical environmental factor that affects
mammalian cell cultures. Traditionally, optimum growth pH for mammalian cell culture
varies between 7.10-7.40 (Borys, et al. 1993; Borys, et al. 1994; Yoon, et al. 2005). In
CHO cells, variation in pH significantly influences several aspects of cell culture
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including cell growth, metabolism and recombinant protein production (Borys, et al.
1993; Kantardjieff, et al. 2011; Miller, et al. 1988; Trummer, et al. 2006; Yoon, et al.
2005). Specifically, low culture pH (<7.0) can result in improved cell viability, prolonged
cultivation time and enhanced recombinant protein yield (Miller, et al. 1988; Trummer, et
al. 2006; Trummer, et al. 2006; Yoon, et al. 2005). For example, Trummer et al (2006)
observed the highest concentration of fusion protein EPO-Fc due to prolongation of CHO
cell culture at pH 6.80. Cell metabolism is also significantly affected by culture pH. Yoon
et al. (2005) observed decreased consumption of glucose and corresponding decrease in
production of lactate at low pH. The reduction in glucose metabolism caused decrease in
cell growth rates (Miller, et al. 1988; Trummer, et al. 2006; Yoon, et al. 2005). Based on
these observations of reduced glucose consumption and lactate production at the pH
range of 6.80 to 7.10 in multiple antibody producing cell lines, an acidic feed for a largescale CHO culture was utilized to reduce lactate production by 60% (Kantardjieff, et al.
2011). Often times, the growth optimal pH is not necessarily the optimal pH for increased
protein production. In mouse hybridoma cell line producing antibody, it was observed
that specific antibody production rate were three times higher at pH 6.80 compared to the
pH of 7.10-7.40 where pH 7.10-7.40 is ideal for growth (Miller, et al. 1988). In contrast,
Borys et al. (1993) observed that the pH for maximum specific recombinant protein
production to be same as optimum growth pH for two CHO cell lines secreting mouse
placental lactogen proteins (Borys, et al. 1993). Additionally, variable response in
specific protein productivity has been observed due to changes in pH in CHO cells
(Borys, et al. 1993; Miller, et al. 1988; Trummer, et al. 2006). While Trummer et al.
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(2006) observed no change in specific productivities in CHO cells producing EPO-Fc
between pH range from 6.80 to 7.60, Borys et al. (1993) reported variations in specific
productivity of mouse placental lactogen protein between pH 6.10 and 8.70 (Borys, et al.
1993; Trummer, et al. 2006).
Variations in pH can also influence glycosylation, an important post-translational
modification that influences protein efficacy (Borys, et al. 1993; Borys, et al. 1994;
Hayter, et al. 1993; Yoon, et al. 2006b). At extreme pH (pH < 6.80 and pH > 8.20),
decreasing levels of glycosylation (reduced efficacy) were observed in mouse placental
lactogen-I produced by CHO cells grown in T-flask cultures, where pH was not
controlled (Borys, et al. 1993). Under a pH-controlled environment, glycosylation was
not affected for any pH in the range of 6.85 to 7.60 (Yoon, et al. 2005). Additionally,
metabolic waste products such as ammonia have been observed to decrease glycosylation
levels of a protein in a pH dependent manner (Borys, et al. 1994; Harcum 2005). Despite
being one of the most basic and critical parameters, currently there are no known
transcriptome studies in literature understanding the response of CHO cells or other
mammalian cells to extracellular pH variations. Nevertheless, transcriptome responses to
pH stresses observed in several bacterial strains indicated gene expression changes
related to key cellular functions such as metabolism, transport, and oxidative stress (Brat,
et al. 2009; Kannan, et al. 2008; Leaphart, et al. 2006; Wilks, et al. 2009). These literature
results suggest that the optimal pH for growth and protein production need to be
determined for every recombinant cell line due to the lack of clear understanding of the
cellular mechanisms. To further elucidate the mechanism of pH effect on CHO cell
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culture, transcriptome understanding of the pH influence on CHO cell culture is
necessary.

2.3.4 Glucose studies
For a majority of the mammalian cell lines, glucose serves as the primary carbon
source required for growth and maintenance. Several important metabolic pathways such
as glycolysis, pentose pathway and TCA cycle are all involved in the catabolism of
glucose. Key intermediates for the synthesis of cellular components such as lipids, sugar
chains and nucleic acids are generated during glycolysis (Ozturk and Hu 2005).
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Figure 2.3: Simplified A) glycolysis and B) tricarboxylic acid (TCA) cycle
showing basic glucose metabolism. Abbreviations: AcCOA – Acetyl coenzyme A
synthetase, AKG – Alpha-ketoglutarate, Cit – Citrate, Fum – Fumarate, Mal – Malate,
Suc – Succinate, Pyr – Pyruvate, Pyr.m – Pruvate (Mitochondrial).
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Most mammalian cell culture media, including serum-free media, typically
contain glucose concentrations between 25 mM to 35 mM (~4.5 g/L to 6.5 g/L).
However, glucose concentrations above 10 mM glucose are analogous to diabetic levels
in humans, suggesting that the mammalian cells are cultivated in excess glucose
(American Diabetes Association 2008). In the presence of excess extracellular glucose
concentrations, the rate of glycolysis in CHO cells is high, as single cells have no means
to regulate the uptake of glucose. This results in CHO cells consuming large quantities of
glucose and subsequent production of metabolic waste like lactate as shown in Figure 2.3
(Ozturk and Hu 2005). The production of lactate, due to incomplete oxidation of glucose,
is energy inefficient, producing 2 moles of ATP as opposed to 36 moles of ATP during
complete oxidation of glucose through glycolysis and TCA cycle (Ozturk and Hu 2005).
The conversion of pyruvate to lactate is also coupled with the regeneration of NAD+ from
NADH, where NAD+ is necessary to sustain high glycolytic flux (Mulukutla, et al. 2010;
Mulukutla, et al. 2012; Seth, et al. 2006). The low energy produced due to incomplete
glucose oxidation results in higher glucose consumption rates and inevitably leads to
increased lactate production, which can inhibit CHO cell growth and negatively affect
protein productivity (Mulukutla, et al. 2010; Ozturk and Hu 2005). Interestingly,
metabolic flux analysis of recombinant CHO cells in a fed batch culture revealed high
glycolytic activity, lactate production and low oxidative metabolism was associated with
maximum growth rates observed during early exponential phase (Templeton, et al. 2013).
In contrast, the protein production phase was positively correlated with oxidative TCA
cycle flux. Lactate production in large-scale culture additionally causes osmolarity
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changes, especially when online pH control via base additions are used to counteract the
pH decrease cause by lactate (Templeton, et al. 2013). In late stages of fed batch cultures,
a metabolic shift towards lactate consumption can occur, alleviating the inhibitory effect
of lactate, improving cell viability and increasing protein titers (Mulukutla, et al. 2012).
The lactate shift primarily occurs at low glucose levels and high lactate concentrations
but is also observed during high glucose concentration when lactate concentrations
become inhibitory to glycolysis (Mulukutla, et al. 2012).
For over 25 years, several approaches have been attempted to minimize lactate
buildup in CHO cell cultures but the problem still persists. Cell engineering approaches
to control lactate production included down-regulation of lactate dehydrogenase (LDH),
overexpression of pyruvate carboxylase or regulating glucose transporters to reduce
glucose flux but were unsuccessful (Seth, et al. 2006). For example, limiting LDH
activity in CHO cells reduced specific lactate production; however the lactate yield from
glucose remained unchanged (Seth, et al. 2006). Alternatively, maintaining low glucose
concentrations has been attempted to reduce the glucose intake by cells. In a continuous
culture of CHO cells, Hayter et al. (1992) observed low concentrations of glucose (2.75
to 4.25 mM) were associated with decreasing glucose consumption rates and low yields
of lactate from glucose (Hayter, et al. 1992). In a separate study, low glucose
concentrations (5 mM) exerted little change on CHO cell intracellular metabolites
including ATP, amino acids and organic acids involved in TCA cycle (Lu, et al. 2005).
However, further studies are required to fully understand the complexity of glucose
metabolism.
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CHAPTER THREE
TRANSCRIPTOME-WIDE PROFILING OF CHINESE HAMSTER OVARY (CHO)
CELL LINES USING RNA-SEQ TO IDENTIFY CRITICAL GENE EXPRESSION
BOTTLENECKS IN SERUM-FREE MEDIUM ADAPTATION PROCESS

3.1 Abstract
Chinese hamster ovary (CHO) cell lines are a well-established mammalian cell line used
for over 25 years, in the biopharmaceutical industry for the production of recombinant
protein therapeutics. CHO cell lines are the preferred host for protein expression due to
their ability to perform human-like post-translational modification of the product protein,
ease of culturing in large-scale bioreactors and protein expression stability. Like most
mammalian cells, parental CHO cell lines are grown as adherent cells in serum
supplemented media. Due to regulatory issues about the use of serum, CHO cells are
grown as suspension cells in serum-free media in large industrial bioreactors. Hence,
CHO cell lines have to be adapted to serum-free media by gradual reduction of serum in
media. Adaptation of CHO cells to serum-free media is a tedious, sensitive process and
can take anywhere between 2-6 months for the cells to be fully adapted. Current literature
on the serum-free adaptation process is limited and not completely understood. The
objectives of this study are to elucidate the transcriptional changes during the process of
serum-free adaptation of CHO cells to gain a better understanding of the adaptation
process and to identify potential targets for adaptation optimization. Two CHO cell lines
were gradually adapted to serum-free medium: CHO DP-12 – an IgG producing cell line
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and CHO DHFR- – the parental cell line. Although CHO DP-12 completely adapted to
serum-free medium, the CHO DHFR- cells could not successfully proceed beyond
medium containing less than 5% serum. For transcriptome analysis, RNA was extracted
from the two cell lines at different stages of serum-free adaptation and sequenced by
Illumina HiSeq 2500. Transcriptome analysis identified serum sensitive genes in both
rCHO DP-12 and CHO DHFR-. Additionally, the differences between the two CHO cell
lines that contributed to the adaptation of CHO DP-12 and hindered the adaptation of
CHO DHFR- were identified. Additionally, Serum sensitive genes in several functional
classes such as glycosylation, apoptosis and cell cycle genes were investigated.
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3.2 Introduction
CHO cells are widely used in the biopharmaceutical industry, particularly in the
manufacture of recombinant protein therapeutics including antibodies, interferons, blood
factors and growth factors (Butler and Meneses-Acosta 2012; Datta, et al. 2013;
Kantardjieff and Zhou 2013; Omasa, et al. 2010). It is estimated that over 35% of the
biopharmaceuticals commercially available are manufactured using CHO cells,
accounting for more than $100 billion in global revenues (Bandaranayake and Almo
2013; Jayapal, et al. 2007; Kantardjieff and Zhou 2013). Even though there are several
mammalian cell line options, the popularity of CHO cells is due to several advantages
offered by it including easy scale up to large-scale processes, well-developed transfection
systems for easy recombinant protein expression and the ability to perform humancompatible protein post-translational modifications (Kim, et al. 2012; Omasa, et al. 2010;
Wuest, et al. 2012).
The culture media used at small scale for most mammalian cells, including CHO
cells, require the addition of 10% serum, mainly fetal bovine serum (FBS), to support cell
growth (Gstraunthaler 2003; Ozturk and Hu 2005; Shah 1999). The use of serum,
however, is associated with several disadvantages, such as not being completely defined,
batch-to-batch variability, serum protein interference in purification process, and most
importantly, serum is a potential source of contaminants, such as bacteria, viruses,
mycoplasma, and prions (Freshney 2005; Ozturk and Hu 2005; Schröder, et al. 2004;
Wessman and Levings 1999). For the aforementioned reasons, the use of serum in the
biopharmaceutical production processes complicates regulatory approval and can
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compromise process robustness (Even, et al. 2006). Hence, CHO cells are preferred to be
cultured in serum-free medium for commercial production processes. In order to
transition from a small-scale laboratory process to a large-scale commercial process,
CHO cells are often adapted to serum-free medium; but the adaptation process is tedious
and can take anywhere between 2-6 months (Astley and Al-Rubeai 2008; Baik, et al.
2011; Rasmussen, et al. 1998; Rodrigues, et al. 2013; Sinacore, et al. 1996). The
reduction of nutrient-rich serum from the medium during the adaptation process for CHO
cells often results in growth declination, disturbances in cell cycle progression, activation
of apoptosis pathways and cell death (Rodrigues, et al. 2013; Zhu, et al. 2006).
Additionally, serum removal has also been reported to impact protein productivity and
protein glycosylation quality (Costa, et al. 2013; Gawlitzek, et al. 1995; LeFloch, et al.
2006; Watson, et al. 1994). To minimize the effects of serum withdrawal, CHO cells are
normally adapted to serum-free medium by gradually lowering serum concentrations in a
step-wise manner over several weeks. Sinacore et al. (2000) described a three-step
protocol to adapt mammalian cells, particularly CHO cells, to serum-free and highdensity suspension cultures (Sinacore, et al. 2000); however the adaptation process is
highly dependent on the cell type (Rodrigues, et al. 2013).
Adaptation of CHO cells to serum-free medium has these long timelines and
negative attributes partly due to an inadequate understanding of serum-free medium
adaptation of CHO cells at cellular and molecular level. Currently, only limited studies
have examined the serum-free adaptation process of mammalian cell lines using ‘omicsbased techniques (Baik, et al. 2011; Jaluria, et al. 2008; Zander and Bemark 2008). These
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studies have identified changes at transcriptome and proteome level occurring in serumfree adapted cells using techniques such as DNA microarrays and 2-Dimensional SDSPAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). However, a global
understanding of the serum-free medium adaptation process is still lacking. The advent of
RNA-Seq, which utilizes high-throughput deep sequencing technology, enables the
profiling of the whole transcriptome and offers several advantages over DNA microarray
techniques, including wider detection range, avoids cross-hybridization, high
reproducibility and consistency (Fu, et al. 2009; Marioni, et al. 2008; Mortazavi, et al.
2008). The recent establishment of parental CHO-K1 and Chinese hamster reference
genome has opened up new avenues for understanding CHO cells, which was not
previously possible (Lewis, et al. 2013; Xu, et al. 2011).
In this study, high-throughput next-generation transcriptomic technology, RNASeq, was utilized to characterize and understand the serum-free medium adaptation
process. RNA samples were extracted from two CHO cell lines – a recombinant CHO
DP-12 cell line and a non-recombinant parental CHO DHFR- cell line, at different
adaptation stages to monitor the changes occurring in the transcriptome. The objective of
the investigation was to identify critical genes and gene families required for successful
serum-free adaptation by characterizing the transcriptional differences during the serumfree medium adaptation process for CHO cells. The impact of serum-free medium
adaptation process on protein glycosylation, cell cycle and apoptosis gene expression was
additionally evaluated. Gene expression differences between the successfully adapted
recombinant CHO cell line and the unsuccessful non-recombinant CHO cell line were
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also identified to gain insights into genes that may support/hinder successful serum-free
medium adaptation process.

31

3.3 Materials and Methods
3.3.1 CHO Cell Lines, Medium, Culture Conditions, and Quantification
All CHO cell lines were obtained from the American Type Culture Collection
(ATCC). The recombinant cell line rCHO DP-12 (ATCC® CRL-12445™) produces a
human monoclonal antibody (IgG1) against Interluekin-8 (IL-8). CHO DHFR- (ATCC®
CRL-9096™) is a non-recombinant cell line and the parental cell line of CHO DP-12.
Both CHO cell lines were originally cultured in Dulbecco’s Modified Eagle medium
(DMEM) (Life Technologies, NY, USA), which contained 4.5 g/L glucose and 10% v/v
FBS (Life Technologies, NY, USA) supplemented with 5mM L-glutamine (Life
technologies, NY, USA) and 10 µg/mL ciprofloxacin-HCl (Mediatech Inc., VA, USA).
Additionally, CD CHO medium (Life technologies, NY, USA), a chemically defined
protein-free and serum-free medium, containing 6 g/L glucose and supplemented with 5
mM L-glutamine (Life Technologies, NY, USA) and 10 µg/mL ciprofloxacin-HCl
(Mediatech Inc., VA, USA) was for the serum-free medium adaptation experiments.
Cells were grown in 25 cm2 flasks (Corning Inc, NY, USA) in an incubator maintained at
37°C and humidified 5% CO2 atmosphere. Suspension cultures were shaken at 120 rpm.
Anti-clumping agent (Life technologies, NY, USA) was added (1:250) to the CD CHO
medium. Cell concentrations were measured using a Scepter 2.0 Handheld Automated
Cell Counter (Millipore, MA, USA). Glucose and lactate measurements were performed
using Yellow Springs Instruments (YSI) 2900 Biochemistry Analyzer (Yellow Springs,
OH, USA). Statistical analysis to find differences in growth rates was performed using
JMP software (SAS institute, NC, USA).
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3.3.2 Adaptation to Serum-Free Medium
For the prescriptive serum-free medium adaptation process, both CHO cell lines
were gradually shifted to lower serum concentrations by increasing the proportion of CD
CHO medium relative to the DMEM with 10% FBS. For example, three parts DMEM
with 10% FBS mixed with one part CD CHO contains 7.5% serum. Cells were seeded at
a concentration of 2 x 105 cells/mL in medium with the next lower serum concentration.
The cells were considered to be adapted to a serum concentration when all three criteria
met for at least three passages: 1) high cell viabilities were reached (greater than 90%
viability), 2) high cell concentrations were reached (greater than 1.5 x106 cells/mL), and
3) normal cell doubling times were observed (less than 24 hours). Once the cells were
adapted to a particular serum concentration, stock cultures were prepared and frozen. The
cells were migrated to a medium with a lower serum concentration and the process was
repeated until the cells had adapted to a serum-free medium or the cells would not adapt
to a lower serum concentration.

3.3.3 RNA Isolation
For transcriptome analysis of the serum-free adaptation process, CHO cell
samples at different stages of adaptation were collected for the two CHO cell lines (rCHO
DP-12 and CHO DHFR-), in biological duplicates. Total RNA samples were collected
from the mid-exponential growth phase, where RNAprotect® cell reagent (QIAGEN,
Hilden, Germany) was added to the cell broth to stabilize the RNA. The total RNA was
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extracted, by using RNeasy plus mini kit, into a 1.5 mL RNAase-Free, DNAase-Free tube
and stored in -80°C (QIAGEN, Hilden, Germany). NanoDrop 8000 UV-Vis
spectrophotometer (Thermo Scientific, MA, USA) and Agilent 2100 Bioanalyzer System
(Agilent Technologies, CA, USA) were used to confirm the quality of the RNA samples.

3.3.4 Library Synthesis, Sequencing and Reference Mapping
The cDNA libraries for whole transcriptome sequencing were constructed by
following the recommended protocol of the TruSeq RNA sample preparation v2.0 kit
(Illumina, San Diego, CA). Briefly, messenger RNA (mRNA) was enriched from total
RNA using poly-T magnetic beads. The mRNA was cleaved into fragments by a nonspecific RNA endonuclease and the fragmentation products were synthesized into
complementary DNA (cDNA) using reverse transcriptase and DNA polymerase enzymes,
respectively. The cDNA products were end repaired to flush, A-tail, and phosphorylate
the DNA ends. These products were then ligated to adapters that serve as priming sites
for enrichment by PCR to create the cDNA libraries for sequencing. Each library
contained an individual specific DNA index used for multiplexing during massively
parallel sequencing. The cDNA libraries were quality validated on an Agilent 2100
Bioanalyzer System to ensure proper fragment distribution (~260 bp) and removal of
adapter dimers. Sequence libraries were multiplexed and sequence data collected on two
lanes of a HiSeq 2500 (Illumina, San Diego, CA) at the Genomics division of David H.
Murdock Research Institute (Kannapolis, NC) using a 2 × 101 bp, paired end read type.
Raw sequence reads were de-multiplexed on the instrument and reads greater than or
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equal to 36 bp were cleaned of adapter and low quality bases (less than Phred 15) with
the Trimmomatic software package (Bolger, et al. 2014).
The trimmed reads obtained were mapped on to the Chinese hamster reference
genome sequence (RefSeq AMDS00000000, AMDS01000000) with the Subread Aligner
(v1.4.5) (Liao, et al. 2013b). Subread performed local alignment of the reads and reported
the locations with the largest overlap among the reads. FeatureCounts was used to assign
the reads to the target genes and summarized the data into a read counts table (Liao, et al.
2013a). The read counts tables were subsequently used as input for the differential gene
expression analysis.

3.3.5 Differential Gene Expression Analysis and Gene Ontology Analysis
Differential gene expression analysis of the RNA-seq data used the edgeR
software package for data filtering and statistical analysis (Robinson, et al. 2010). The
software edgeR utilizes a negative binomial distribution model to capture the quadratic
mean-variance relationship common to RNA-Seq data (Chen, et al. 2014; Robinson and
Smyth 2008). Additionally, edgeR employs an empirical Bayes method to stabilize overdispersion across genes by sharing information across all observations including
replicates (McCarthy, et al. 2012; Robinson and Smyth 2007; Robinson, et al. 2010). The
steps used for RNA-Seq statistical analysis were a) filtering low expressed genes, b)
normalizing the library, c) plotting the multidimensional scaling graph, d) identifying
differentially expressed genes using generalized linear model and e) analyzing genes for
overrepresentation by gene ontology (GO) enrichment analysis using GOseq. The
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filtering criteria used to remove genes with low expression was that a gene needed to
have greater than 10 count-per-million (CPM) in at least two samples (Appendix A.1)
(Anders, et al. 2013). The 10 count-per-million was selected based on the point of
influxion from the plot of normalized expression level arranged in ascending order of
expression. The library sizes for all samples were normalized using trimmed mean of Mvalues (TMM) method in edgeR (Robinson and Oshlack 2010). The multidimensional
scaling (MDS) plot was used to visualize the similarities and dissimilarities between the
replicates and samples (Appendix B.1). Additionally, an estimation of tagwise dispersion
related to the design matrix was conducted using the quantile-adjusted conditional
maximum likelihood (qCML) method (McCarthy, et al. 2012). To identify the
differentially expressed genes, a one-way unbalanced layout with each condition as
individual group was used for all pairwise comparisons. A Benjamini-Hochberg
procedure was used to control for false discovery rates (FDR) and FDR ≤ 0.01 was used,
unless otherwise specified (Benjamini and Hochberg 1995). The differentially expressed
genes were used for gene ontology enrichment analysis using the goseq software – a R
based Bioconductor package (Young, et al. 2012). GOseq accounts for selection bias for
long and overexpressed gene sequences by calculating the Probability Weighting
Function (PWF) (Oshlack and Wakefield 2009). For GO analysis, goseq uses two vectors
– one containing all the measured genes and the other containing the differentially
expressed genes. Additional information containing genes length and the GO categories
associated with the genes were supplied. GO terms with p ≤ 0.05 from the overrepresentation test were considered to be statistically significant. Additionally, manual

36

screening of gene and gene families, that had common stem in its gene symbol, with
greater than 1.5-fold expression change was performed to identify genes sensitive to
serum-free medium adaptation process.
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3.4 Results and Discussion
Previously, several reports have described the adaptation to serum-free medium
for CHO cells and a few other mammalian cell lines (Lang, et al. 1991; Ozturk, et al.
2003; Sinacore, et al. 2000). All of these methods share a common attribute, in that; the
procedures are long, tedious and labor-intensive. Figure 2.2 compares the timelines of
serum-free medium adaptation for CHO cell lines. From the timeline, it can be clearly
seen that the recombinant CHO cell lines, rGS-CHO and rCHO, on average adapted
much quicker to serum-free medium than the non-recombinant CHO cell lines CHO-K1,
CHO DUKX and CHO DUXB11. Our earlier work to adapt the rCHO DP-12 and CHO
DHFR- cell lines to a common serum-free medium using an ad-hoc adaptation process,
also observed that the recombinant cell line adapted more quickly (data not shown).
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3.4.1 Prescriptive serum-free medium adaptation process for rCHO DP-12 and
CHO DHFRIn this study, rCHO DP-12 and CHO DHFR- were adapted to serum-free medium
by gradually reducing the serum concentration by increasing the proportion of CD CHO
medium and decreasing the portion of DMEM medium in the culture media. The CHO
cells were considered to be adapted to a particular serum concentration when all three
criteria were reached for at least three passages: 1) high cell viabilities (greater than 90%
viability), 2) high cell concentrations (greater than 1.5 x 106 cells/mL), and 3) normal cell
doubling times (less than 24 hours). Once the cell line was adapted, the CHO cells were
migrated to a medium with a lower serum concentration.
The serum-free medium adaptation timelines for rCHO DP-12 and CHO DHFRare shown in Figure 3.2. The rCHO DP-12 cells were successfully adapted to serum-free
medium (0% serum) within 65 days. In contrast, the non-recombinant parental CHO
DHFR- cell line was only successfully adapted to 5% serum at 65 days, and failed to
adapt to serum-free medium, even after 120 days. Adaptation of the CHO DHFR- cells to
any serum concentration below 5% was not successful, even when 4% serum was
attempted, instead of the normal decrease to 2.5% serum. The adaptation timelines for the
rCHO DP-12 and CHO DHFR- cell lines observed in this study are consistent with the
adaptation timelines observed in the literature (Figure 2.2). The apparent increased
robustness of the recombinant CHO cell lines might be attributed to the various selection
and amplification steps used to generate these recombinant cell lines, i.e., using toxic
chemicals such as dimethyl methotrexate(Mariani and Schimke 1984).
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Figure 3.1: Serum-free medium adaptation timelines of the two CHO cell lines, rCHO
DP-12 and CHO DHFR-, used in this study. The downward black arrows indicate the
different adaptation steps during which RNA samples were harvested. The dashed arrow
at the end of CHO DHFR- timeline indicates the unsuccessful adaptation attempts beyond
5% serum.
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In order to characterize the CHO cell transcriptional landscape at different points
in the serum-free medium adaptation process, RNA-samples were isolated from both
CHO cell lines cultured in the different serum concentrations – 10%, 5% and 0% serum
for rCHO DP-12 and 10% and 5% serum for CHO DHFR-. The growth profiles for these
five culture conditions are shown in Figures 3.2A and 3.2B. Figure 3.2A shows the
growth profiles of the cultures in 10% serum, which are anchorage-dependent, while
Figure 3.2B shows the growth profiles of the cultures in 5% and 0% serum, which were
in suspension. The growth rates for rCHO DP-12 and CHO DHFR- cells at 10% serum
were the same at 0.026 h-1. The growth rates observed for the CHO cells in 5% serum
were not significantly different for the two cell lines, at 0.035 h-1 (p < 0.05), after
omitting the first time point at zero hours for CHO DHFR- due to lag in growth during
the first 24 hours of culture. The growth rate of rCHO DP-12 cells in the 0% serum, CD
CHO medium, was 0.036 h-1, which was not significantly different from the 5% serum
rCHO DP-12 culture growth rates (p < 0.05).

41

Figure 3.2: Growth profiles of rCHO DP-12 and CHO DHFR- grown at different serum
concentrations during the adaptation process. CHO DP-12 (open) and CHO DHFR(closed) cultivated at A) 10% serum media (squares) and B) 5% serum media (circles)
and 0% serum media (diamonds) is shown. The black arrows indicate the RNA extraction
from the mid exponential growth phase.
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The RNA samples were taken from the mid-exponential phase for each culture in
duplicates between 44-48 hours as indicated by black arrows in Figure 3.2A and 3.2B. At
the time of RNA harvest, glucose concentration was not limiting (> 15 mM) and the
lactate concentrations were not inhibitory (< 25 mM) (Appendix 3.3B). RNA-Seq data
obtained from HiSeq 2500 was mapped to the Chinese hamster reference genome (Lewis,
et al. 2013). The raw data mapped to a total of 27,629 genes. As mentioned in the
Materials and Methods, the low count genes were filtered (CPM ≥ 10 in at least two
samples) and the number of genes was reduced to 10,774 genes, which were used for
differential gene expression analysis using a one-way layout. The number of
differentially expressed genes in each of the pairwise comparison is shown in Table 1.
Four of these comparisons represent the main effect of serum as indicated in bold text.
And two comparisons represent the main effect of cell line as indicated in italics. To
identify genes most sensitive to serum, three of the four serum pairwise comparison gene
groups were analyzed using a Venn diagram. The comparison of rCHO DP-12 in 0%
serum to 10% serum was not used. Figure 3.3A and 3.3B shows the Venn diagram of
these three pairwise comparisons, segregated by genes that had higher and lower
expression between the pairs, respectively (FDR ≤ 0.01). Three of the intersections from
Venn diagram represent genes that provide insight into the serum-free adaptation process.
The first intersection is the intersection of all three groups and has 185 higher expression
genes and 282 lower expression genes (Figure 3.3A, 3.3B). This intersection represents
the genes that were serum sensitive in both CHO cells - rCHO DP-12 and CHO DHFR-,
and was also sensitive throughout the adaptation process in rCHO DP-12. The second
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intersection, which is only between the rCHO DP-12 groups, has 251 higher expression
genes and 350 lower expression genes (Figure 3.3A, 3.3B). This intersection represents
the genes that had continued to be serum-sensitive in rCHO DP-12 throughout the
adaptation process. The third intersection represents the genes that had common
responses in both cell lines during the adaptation from 10% serum to 5% serum. This
group has 766 higher expression genes and 572 lower expression genes. These genes
represent gene expression changes necessary for adaptation to 5% serum medium. These
groups were used for functional analysis of groups such as glycosylation, apoptosis and
cell cycle, and gene ontology (GO) enrichment analysis.
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Table 3.1: Pairwise comparisons of rCHO DP-12 and CHO DHFR- between the cell lines
and different serum concentrations (FDR ≤ 0.01). Numbers in parenthesis indicate the
number of genes with greater than 1.5-fold difference in expression. The numbers in bold
represent comparisons where the serum adaptation was the main effect. The numbers in
italics represent comparisons where the cell line was the main effect.
Cell
Lines

Serum
10%

rCHO
DP-12

5%

10%

rCHO DP-12
5%
0%
4363
6066
(1712)
(3006)
4667
(1790)

0%
CHO
DHFR-

10%
5%
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CHO DHFR10%
5%
4229
6159
(1803)
(2034)
5149
5467
(2300)
(2298)
6166
6479
(3187)
(3319)
4045
(1461)

Figure 3.3: Venn diagram of three pairwise comparisons – DP12 5%/10%, DP12 0%/5%
and DHFR 5%/10%, with serum as the main effect to identify common serum sensitive
genes. Differentially expressed genes in these comparisons were separated into A) Higher
expression and B) Lower expression to identify the genes most sensitive to serum (FDR ≤
0.01).
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3.4.2 Influence of the serum-free medium adaptation process on glycosylation gene
expression
CHO cells are widely used in biopharmaceutical industry to produce recombinant
glycosylated proteins with therapeutics/diagnostic uses (Jayapal, et al. 2007; Kantardjieff
and Zhou 2013). One of the major advantages of using CHO cells is its ability to perform
human-like post-translational modifications. Glycosylation, a post-translational
modification, is a critical product quality attribute that dictates efficacy, immunogenicity
and stability of the therapeutic protein (Walsh and Jefferis 2006). Consistent protein
glycosylation is required to obtain regulatory approval (Hossler, et al. 2009). Several
studies have documented the impact of serum-free medium adaptation on the
glycosylation patterns of the recombinant proteins; however no study has investigated the
impact of the adaptation process on glycosylation gene expression (Costa, et al. 2013;
Gawlitzek, et al. 1995; LeFloch, et al. 2006). To assess the impact of the serum-free
medium adaptation process on CHO cell protein glycosylation, the gene expression levels
for 264 glycosylation-related genes were compared with the three interaction lists – 1)
genes that were serum sensitive in both CHO cells, 2) genes that were serum sensitive in
rCHO DP-12 only and 3) genes that were sensitive to transition from 10% to 5% serum in
both CHO cells. Overall, 38 glycosylation related genes were impacted by serum-free
medium (Table 2). Of the 38 genes, there were 11 genes that were of importance from the
biopharmaceutical standpoint and they can be broadly categorized into four groups:
sialidase (Neu2), sialyltransferases (ST3gal2, ST3Gal3, ST3Gal4, ST3Gal5),
fucosyltrasnferase (Fut8, Pofut2) and mannosidase (Man1a2, Man2b1).
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Table 3.2 - Glycosylation-related genes sensitive to serum-free medium adaptation
process (FDR ≤ 0.01)

Gene
DP12
Symbols
Gene Family
0/5
Genes sensitive to serum in both CHO cells
Chst11
Sulfotransferases
-4.9
Cmas
Nucleotide Synthesis
-1.5
Extl2
GlcNAc-transferases
-1.7
Fut8
Fucosyltransferases
-2.1
Galnt1
GalNAc-transferases
-1.4
Hk1
Nucleotide Synthesis
-1.2
Lfng
GlcNAc-transferases
-1.4
Man1a2
Mannosidase
-1.9
Neu2
Sialidases
-30.9
Slc35a3
Nuc. Sugars Transporters
-1.8
St3gal3
Sialyltransferases
1.6
St6galnac6
1.9
Sialyltransferases
Ugp2
Nucleotide Synthesis
1.7

Fold Change
DP12
DHFR
5/10
5/10
-1.5
-3.0
-1.7
-1.4
-4.3
-1.4
-1.9
-1.4
-9.9
-1.5
1.5
1.2
1.3

-1.4
-1.4
-1.9
-1.4
-1.2
-1.4
-2.6
-1.2
-3.3
-1.5
1.7
1.7
1.7

Genes sensitive to serum in rCHO DP-12 only

Alg6
Extl1
Galnt7
Gba
Gmppa
Gpi
Hpse
Hs6st1
Pofut2
St3gal4
St3gal5

Glucosyltransferases
GlcNAc-transferases
GalNAc-transferases
Lysosomal Enzymes
Nucleotide Synthesis
Nucleotide Synthesis
Heparanases
Sulfotransferases
Fucosyltransferases

1.2
-2.8
2.1
-1.4
-1.6
1.3
-2.6
-1.7
-1.4
1.5
-1.4

Sialyltransferases
Sialyltransferases

1.8
-2.3
1.2
-1.2
-1.2
1.3
-1.6
-2.8
-1.3
1.3
-1.3

2.6

1.4

1.4

Genes sensitive to transition from 10% to 5% serum in both CHO cells

Alg8
Alg9
B4galt2
Extl3
Fuca1

Glucosyltransferases
Mannosyltransferases

1.7

Galactosyltransferases

GlcNAc-transferases
Fucosidases

-1.6
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1.4
-1.3
1.4
1.4
-2.5

1.3
-1.2
1.8
1.5
-1.3

Table 3.2 - Glycosylation-related genes sensitive to serum-free medium
adaptation process (FDR ≤ 0.01)
Galnt11
Glce
Gnpda1
Gusb
Lipa
Man2b1
Pomgnt1
St3gal2
Sulf2

GalNAc-transferases
Miscellaneous
Nucleotide Synthesis
Galactosidase
Lysosomal Enzymes

-1.4

Mannosidase

GlcNAc-transferases
Sialyltransferases

Sulfatases

1.5
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1.4
-1.4
1.7
1.4
1.3
1.5
1.6
-1.6
-4.6

1.5
-1.4
1.7
1.4
1.3
1.9
1.5
-1.2
-1.7

The sialidase gene, Neu2, experienced the highest fold-change during the serumfree medium adaptation process (Figure 3.4A). Neu2 had over 300-fold decrease in
expression throughout the serum-free medium adaptation. Sialidases are a class of
glycosidic enzymes that cleave the terminal monosaccharides, particularly sialic acids,
from the glycoprotein (Miyagi and Yamaguchi 2012). The decrease in Neu2 gene
expression could directly impact the activity of sialidases, thereby affecting sialylation of
glycoproteins. The presence of sialic acid residues can change the physiological role of
IgGs from pro-inflammatory molecule to anti-inflammatory agent (Bork, et al. 2009;
Costa, et al. 2013; Hossler, et al. 2009). The decrease in Neu2 expression is consistent
with higher sialic acid content observed for a IgG1 in serum-free medium and the
decrease in sialylation of interferon-γ due to the presence of serum observed previously
in the literature (LeFloch, et al. 2006).
Two mannosidases, Man1a2 and Man2b1, were observed to be serum sensitive
but change in expression due to the adaptation process was different for both genes
(Figure 3.4B). Man1a2 had a significant decrease in expression during the adaptation
process in both CHO cells, while Man2b1 had a significant increase in expression in both
CHO cells while transitioning from 10% to 5%. Mannosidases are involved in trimming
the mannose residues from the product protein before performing glycan structure
modification. The presence of high mannose structures in the glycoprotein has been
associated with reduced efficacy of the recombinant proteins(Costa, et al. 2013). The
expression of other members of the mannosidases family remained unchanged for most
part of the adaptation process.

50

The sialyltransferase genes were significantly impacted by serum-free medium
adaptation process (Figure 3.4C). ST3Gal3 and ST3Gal4 had an overall increase in
expression during the adaptation process, while ST3Gal2 decrease in its expression
during serum-free medium adaptation. It was interesting to note that while the expression
of ST3Gal5 during the adaptation process decreased in rCHO DP-12, it had an increase in
expression in CHO DHFR-. Sialidase and sialyltranferase gene expression could directly
impact the sialylation of the recombinant protein. The presence of terminal sialic acids
can improve the activity, stability of the glycoprotein and can promote anti-inflammatory
response (Bork, et al. 2009; Hossler, et al. 2009). The overall increase in sialyltransferase
gene expression during adaptation process, in addition to the decrease in Neu2
expression, could improve the sialylation of the protein. Indeed, as noted earlier, studies
have reported increase in sialylation under serum-free medium conditions (LeFloch, et al.
2006; Patel, et al. 1992).
Fut8, which is a major fucosyltransferase gene, had a decrease in expression
during adaptation process in both CHO cells (Figure 3.4D). Additionally, Pofut2, another
fucosyltrasnferase gene, decreased in expression in rCHO DP-12 but it remained
unchanged in CHO DHFR- during the adaptation process. The decrease in expression of
fucosyltransferases could potentially lead to the production of recombinant proteins with
decreased/no fucose residue. The lack of core fucose in antibodies has been observed
with enhanced efficacy through antibody-dependent cell-mediated cytotoxicity (ADCC).
Indeed, Costa et al. (2013) observed lowest level of core fucose concentration at 0.625%
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serum concentration while profiling glycans concentration during the serum-free medium
adaptation (Costa, et al. 2013).
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Figure 3.4: Glycosylation genes significantly impacted by the serum-free medium
adaptation process in rCHO DP-12 and CHO DHFR- (FDR ≤ 0.01). Specifically, the gene
families affected were A) Sialidase, B) Mannosidase, C) Sialiyltransferases and D)
Fucosyltransferases.
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3.4.3 Cell shock related genes
Serum-free medium adaptation process in CHO cells and other mammalian cell
lines often results in cell shock, subsequently leading to growth arrest and cell death. The
shock experienced by cells during the adaptation process is mainly due to the removal of
several nutrients present in serum, such as growth factors, vitamins, and amino acids
(Sinacore, et al. 2000). Thus, the expression of genes related to cell cycle progression and
apoptosis genes were examined at different stages of the serum-free medium adaptation
process.

3.4.3.1 Cell cycle related genes
Cell cycle genes that belonged to various cell cycle phases such as G-phase, Mphase, S-phase and DNA replication genes, as well as regulation related genes such as
cell cycle checkpoint, cell cycle arrest and progression of cell cycle were examined. In
this study, the serum sensitive genes were compared to 84 cell cycle related genes that
were compiled by SABiosciences (Fischer, et al. 2011; Lo, et al. 2010; MertlikovaKaiserova, et al. 2010; Montes, et al. 2011; Wu, et al. 2011). Seventeen cell cycle genes
that were sensitive to the serum-free medium adaptation are listed in Table 3.
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Table 3.3 - Cell cycle-related genes sensitive to serum-free medium adaptation process

Gene Symbols Gene Description
Genes sensitive to serum in both CHO cells
Cdk6
Cyclin-dependent kinase 6
peripheral myelin protein 22,
Pmp22
transcript variant X2

DP12 0/5

Fold Change
DP12 5/10 DHFR 5/10

-1.6

-1.8

-1.9

-1.4

-1.6

-1.4

-1.6

-1.3

-1.3
-1.3

-2.1
-1.9

-1.4
-2.0

-1.3
-1.2

Genes sensitive to serum in CHO DP-12 only

Ccnd3
Cdkn1a
Nek2
Rb1
Stmn1

cyclin D3, transcript variant X1
cyclin-dependent kinase inhibitor
1A (p21, Cip1)
NIMA-related kinase 2
retinoblastoma 1, transcript variant
X2
stathmin 1, transcript variant X2

Genes sensitive to transition from 10% to 5% serum in both CHO cells

Birc5
Ccnd1
Cdkn1b
Cdkn3
E2f2
E2f3
Itgb1
Mad2l1
Notch2
Tfdp1

baculoviral IAP repeat containing
5
cyclin D1
cyclin-dependent kinase inhibitor
1a
cyclin-dependent kinase inhibitor
3, transcript variant X4
E2F transcription factor 2,
transcript variant X2
E2F transcription factor 3,
transcript variant X3
integrin, beta 1 (fibronectin
receptor)
MAD2 mitotic arrest deficient-like
1 (yeast)
notch 2, transcript variant X2
transcription factor Dp-1,
transcript variant X6
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-1.2
-1.3

-1.2
-2.7

1.4

1.8

1.4

1.2

2.0

1.4

-1.4

-1.2

-2.6

-1.5

1.4
-1.5

1.4
-1.4

-1.2

-1.3

Cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors genes
are known to play critical role in the cell cycle progression and cell proliferation. The
gene expression profiles for cyclin dependent kinase inhibitor genes (Cdkn1a, Cdkn1b,
Cdkn3), and cyclin and cyclin-dependent kinase genes (Ccnd1, Ccnd3, Cdk6) are shown
in Figure 3.5A and 3.5B, respectively. Cyclin-dependent kinase inhibitor genes encode
for proteins that function as cell-cycle regulators by binding with the cyclin-dependent
kinases and inhibiting its activity. Of the three cyclin-dependent kinase inhibitor genes
that were serum sensitive, only Cdkn1a gene had significant decrease expression in
rCHO DP-12 throughout the serum-free medium adaptation process. Cdkn1a gene is one
of the most potent and important inhibitor of cell proliferation and the decrease in its
gene expression could be vital in preventing cell cycle arrests during the serum-free
medium adaptation process. For Cdkn1b and Cdkn3, there was no significant change in
expression when transitioning from 5% serum to 0% serum. Interestingly, the expression
of cyclins – Ccnd1 and Ccnd3, and cyclin-dependent kinase - Cdk6, had a decrease in
expression in both CHO cell lines during the adaptation. The decrease in expression of
these CDK and cyclin genes can impact cell cycle progression and cellular proliferation.
The cells were well adapted to the particular serum concentration at the time of RNA
harvest and hence it was rather surprising to see the lower expression of these genes. It
should be noted that the mammalian cells contain 5 different CDK subunits and 10
distinct cyclins that contribute towards cell cycle proliferation (Harper and Adams 2001).
This could indicate that the expression of other members of CDKs and cyclins, which
were not identified to be serum, could be important in regulating cellular proliferation.
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Figure 3.5: Cell cycle genes sensitive to serum-free medium adaptation process. In
particular, the serum sensitive genes belonged to: A) cyclin dependent kinase inhibitors
and B) cyclins and cyclin-dependent kinases.
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3.4.3.2 Apoptosis genes
Serum withdrawal and nutrient limitations of growth factors often represents a
change in nutrient environment leading to growth decline and in some cases, resulting in
the activation of apoptosis (Arden and Betenbaugh 2004; Sinacore, et al. 2000).
Apoptosis generally occurs through two different pathways – an extrinsic pathway (death
receptor) or an intrinsic pathway (mitochondria-mediated) (Arden and Betenbaugh 2004;
Miura, et al. 2012; Wong, et al. 2006). To investigate the impact of serum-free medium
adaptation on apoptosis, the serum sensitive genes were compared to the 84 apoptosis
pathway related genes compiled by SABiosciences were examined(Dutta, et al. 2012;
Mao, et al. 2010; Taylor, et al. 2011; Wu, et al. 2011). Due to the similar nature of
apoptosis and cell cycle activity, there were five genes were in common between the two
lists. Of the 84 apoptosis genes, 15 genes were serum sensitive. Interestingly, the
majority of the serum-sensitive apoptosis-related genes (9) were affected when CHO
cells transitioned from 10% to 5% serum. Anti-apoptotic genes such as Birc3 and Cflar
had at least 1.5-fold change in expression in both CHO cells while transitioning from
10% serum to 5% serum (Figure 3.6A). Birc3 gene encodes for a member of the inhibitor
of apoptosis family. However, Birc3 had decrease in expression in both CHO cell lines
and throughout the adaptation process in CHO DP-12. The decrease in expression Birc3
could potentially lead to unregulated expression of Casp3 and Casp7, leading to
apoptotic cell death. Cflar acts as an inhibitor of tumor necrosis factor receptor (TNFR)
mediated apoptosis and the lower expression of this gene has been associated with
induction of apoptosis. Other anti-apoptotic genes such as Nol3, that also acts an
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apoptosis inhibitor of caspase activities (Casp2, Casp8), had an increase in expression
during the transition. The expression of these genes did not change significantly while
adapting to 0% serum from 5% serum medium (data not shown). Pro-apoptotic genes
such as Casp1 and Nod1 were serum-sensitive in both CHO cells (Figure 3.6B).
Particularly, Casp1 had an increase in expression of over 30-fold as the cells transitioned
from 5% serum to 0% serum. Casp1 has been observed to play a role in apoptosis
induction, particularly in CD-95 mediated apoptosis. However, studies have suggested
other caspases may play a more significant role in apoptosis pathway than Casp1 (Cohen
1997). Nod1 gene encodes for a cytosolic protein that is involved in the apoptotic
signaling and enhancing caspase-9-mediated-apoptosis. In this study, however, at the
time of RNA-extraction, the cells were completely adapted to serum-free medium and the
cells were growing exponentially and no signs of apoptosis were recorded. Generally, the
occurrence of apoptosis has been observed during the later stages of the growth phase. It
is likely that the expression changes of these genes may not be translated into activity in a
linear fashion. Further studies are required at the proteome level to understand the role of
apoptosis during the serum-free medium adaptation.
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Table 3.4 - Apoptosis-related genes sensitive to serum-free medium adaptation process

Gene
Symbols
Gene Description
Genes sensitive to serum in both CHO cells
Bcl2l1
BCL2-Like 1
baculoviral IAP repeat containing
Birc3
3, transcript variant X2
caspase 1, apoptosis-related
cysteine peptidase, transcript
Casp1
variant X1
caspase 7, apoptosis-related
cysteine peptidase, transcript
Casp7
variant X3

Fold Change
DP12
DP12
DHFR
0/5
5/10
5/10
-1.3

-1.2

-1.3

-1.5

-2.1

-2.1

6.0

4.7

31.6

2.1

1.2

1.7

-1.6

-1.3

-2.2

-1.4

Genes sensitive to serum in CHO DP-12 only

Bnip3l
Mcl1

BCL2/adenovirus E1B 19kDa
interacting protein 3-like,
transcript variant X2
myeloid cell leukemia 1,
transcript variant X2

Genes sensitive to transition from 10% to 5% serum in both CHO cells

Akt1
Atf5
Birc5

Bnip2
Cflar

Dffa

v-akt murine thymoma viral
oncogene homolog 1, transcript
variant X2
activating transcription factor 5,
transcript variant X2
baculoviral IAP repeat containing
5
BCL2/adenovirus E1B 19kDa
interacting protein 2, transcript
variant X2
CASP8 and FADD-like apoptosis
regulator, transcript variant X1
DNA fragmentation factor,
45kDa, alpha polypeptide,
transcript variant X2
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Table 3.4 - Apoptosis-related genes sensitive to serum-free medium adaptation
process

Nod1

Nol3
Xiap

nucleotide-binding
oligomerization domain
containing 1, transcript variant
X1
nucleolar protein 3 (apoptosis
repressor with CARD domain),
transcript variant X1
X-Linked Inhibitor Of Apoptosis
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Figure 3.6: Apoptosis related genes that were affected by serum-free medium adaptation
process. Serum sensitive genes were divided into: A) Anti-apoptosis and B) pro-apoptosis
genes.
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3.4.4 Gene ontology Enrichment analysis
The serum sensitive genes identified from the intersections of the three serumrelated pairwise comparisons were used for gene ontology (GO) enrichment analysis by
GOseq software to identify biological processes that were impacted by serum-free
medium adaptation process. Gene ontology is way to represent a gene and gene product
properties, particularly through three domains – cellular component, molecular function
and biological process. For GO analysis, the higher and lower expression genes were
combined for each list before performing the enrichment analysis. For the 10,774 filtered
genes used for differential gene expression analysis, over 45% of the genes had go terms.
Enriched GO terms that had 5 or more genes in its category were considered to be
meaningful.
The GO enrichment analysis for the 467 genes that were serum sensitive in both
CHO cell lines identified enriched genes belonging to13 different GO categories.
However, none of these GO terms had five or more genes enriched in the category, and
hence could not be studied. The GO enrichment analysis of the 651 genes that were
serum sensitive only in rCHO DP-12 cells recognized genes enriched in five different GO
categories; two GO terms had five or more genes in its category - protein transport and
lipid metabolic process (Table 3.5). Of the 11 genes representing protein transport GO
term, all but one gene had a decrease in expression throughout the serum-free medium
adaptation in rCHO DP-12. Five of these genes encode for proteins that belong to the
small GTPase family, that are known to regulate membrane trafficking. Only two genes,
Rab43 (small GTPase family) and Rras, had a decrease in expression of greater than 1.5-
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fold in both comparisons – rCHO DP-12 0%/5% and rCHO DP-12 5%/10% (Figure 3.7).
Rras gene codes for a protein that can increase the adhesiveness of integrins to the
substrate (Dejgaard et al. 2008, Hood et al. 2002). The decrease of Rras could be linked
with the transition of cells from adherent growth phenotype to suspension growth
phenotype and the consequent decrease in cell-matrix binding. Rab43 is involved in
anterogradte/reterograde trafficking of proteins from ER to Golgi. The decrease in Rab43
gene expression has been observed to cause Golgi redistribution but without affecting the
trafficking of proteins from ER to cell surface. The impact of Rab43 expression needs to
be further investigated in relation to serum-free medium adaptation. Interestingly, the
expression of Rab43 and Rras genes in CHO DHFR- was opposite of that observed in
rCHO DP-12, i.e. the expression increased when transitioning from 10% serum to 5%
serum. There were six genes in lipid metabolic process category and three genes had over
1.5-fold change in both comparisons: rCHO DP-12 0%/5% and 5%/10%. Few of the
genes in this group code for proteins related to patatin-like phospholipase domain
containing protein family. The members of this family catalyze the cleavage of fatty acids
from membrane phospholipids. However, the exact relevance of these genes with serumfree medium adaptation was not clearly understood.
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Table 3.5 - Enriched GO terms for genes sensitive in rCHO DP-12 only
Gene
Symbol

Fold Change
DP-12
DP-12
DHFR
5%/10% 0%/5% 5%/10%

Gene Name

Protein transport (GO:0015031)
Arf4
ADP-ribosylation factor 4
Arl8a
ADP-ribosylation factor-like 8A
RAB43, member RAS oncogene
Rab43
family, transcript variant X2
RAB5A, member RAS oncogene
Rab5a
family, transcript variant X2
RAB7A, member RAS oncogene
Rab7a
family
RAP1A, member of RAS
Rap1a
oncogene family
RAP1B, member of RAS
Rap1b
oncogene family
ras homolog family member C,
Rhoc
transcript variant X2
related RAS viral (r-ras) oncogene
Rras
homolog, transcript variant X2
related RAS viral (r-ras) oncogene
Rras2
homolog 2
translocase of inner mitochondrial
Timm17a
membrane 17 homolog A (yeast)
Lipid metabolic process (GO:0006629)
diacylglycerol lipase, alpha,
Dagla
transcript variant X4
glycerophosphocholine
phosphodiesterase GDE1 homolog
Gpcpd1
(S. cerevisiae), transcript variant
X2
Plcd1
phospholipase C, delta 1
patatin-like phospholipase domain
Pnpla2
containing 2
patatin-like phospholipase domain
Pnpla8
containing 8
trans-2,3-enoyl-CoA reductase,
Tecr
transcript variant X2
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Figure 3.7: Rab43 and Rras gene expression in rCHO DP-12 and CHO DHFR-.
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In contrast to the GO analysis on the previous two lists, the GO enrichment
analysis of the 1,288 genes that were serum sensitive in both CHO cells while
transitioning from 10% to 5% serum recognized five or more enriched genes related to
four different GO categories. The enriched genes were related to oxidation-reduction
process, translation, metabolic process and cell redox homeostasis (Table 3.6). Among
genes related to oxidation-reduction process, majority (~70%) of the genes had increase
in expression during the transition from 10% to 5% serum in both CHO cells and around
40% of the genes had greater than 1.5-fold change in expression in rCHO DP-12 and
CHO DHFR-. Three genes belonging to glutathione peroxidase gene family (Gpx1, Gpx4
and Gpx8) were enriched among the oxidation-reduction genes (Figure 3.8). Glutathione
peroxidase is a major antioxidant enzyme that functions in the detoxification of hydrogen
peroxide. The increase in expression of genes encoding for antioxidant enzymes could
possibly be due to an increase in oxidative stress. This was further supported by increase
in expression of other genes families that code for antioxidant enzymes such as
perodiredoxin, which belonged to the cell-redox homeostasis genes. Serum reduction has
been reported to increase cell susceptibility to oxidative stress and damage, mainly due to
the uncontrolled cellular uptake of iron in the absence of transferrin in serum-free
medium (Rodriguez et al. 2013, Garcia-alfonso 1996). The iron-related oxidative stress
was further indicated through the increase in expression levels of heme oxygenase 1
(Hmox1). Hmox1 is a heat shock protein whose expression levels are induced by heat
shock and other physiological stresses. The presence of excess iron levels has been
observed to increase Hmox1 levels and increase reactive oxygen species (ROS) in human
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hepatoma cells. Moreover, the expression levels of ferritin heavy chain, which assists in
the intracellular storage of iron, were increased in both CHO cells during the transition to
5% serum from 10% serum. The gene expression pattern observed here indicates that the
cells were undergoing oxidative stress, likely through the unregulated uptake of iron.
Interestingly, several of these genes had much higher expression in CHO DHFR- than its
expression in rCHO DP-12, possibly indicating the oxidative stress was greater in CHO
DHFR- cells. Understanding the mechanism of action to counteract this oxidative stress
could be critical for successful serum-free medium adaptation. In rCHO DP-12, several
of these genes did not change in significantly when transitioning from 5% to 0% serum,
possibly indicating the stress was reduced at the later stages of the adaptation process.
Metabolic process GO term consisted of broad category of genes belonging to different
cellular metabolism. Among the genes enriched in the translation GO terms, several of
the genes had very low change in expression. Based on the expression pattern of genes
related to the oxidative stress, we hypothesize that the initial adaptation of cells from
10% serum to 5% serum was could be more critical than the adaptation from 5% to 0%
serum. The changes occurring at this stage could be crucial in preparing the CHO cells
for adaptation to lower serum concentrations in later adaptation process.
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Table 3.6 - Enriched GO terms for significant genes between rCHO DP-12 and CHO K1PF during the transition from 10% serum to 5% serum

Go Term
Cell redox
homeostasis
Metabolic process
Oxidationreduction process
Translation

p-value for
Overrepresentation

Number of
Genes in
Category
Effected

GO:0045454
GO:0008152

2.56E-02
6.32E-05

6
52

34
383

GO:0055114
GO:0006412

1.49E-06
2.64E-06

36
24

212
158

Category
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Figure 3.8: Glutathione peroxidase genes in rCHO DP-12 (open) and CHO DHFR(closed) during the serum-free medium adaptation process
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3.4.5 Gene expression differences between rCHO DP-12 and CHO DHFR- related to
serum-free medium adaptation behavior
Of the two CHO cell lines used in this study, the serum-free medium adaptation
process was successful only in one - rCHO DP-12. CHO DHFR- cells were unable to
grow beyond medium containing 5% serum medium. The identification of differences in
gene expression between rCHO DP-12 and CHO DHFR- will aid in further understanding
of the serum-free adaptation process and in identifying critical gene expression pattern
necessary for successful serum-free medium adaptation process. A statistical interaction
test was used to identify genes with varying behavior between the two cell lines during
adaptation to 5% serum from 10% serum. For example, if a significant gene had a
positive fold-change in this comparison, it meant that the gene expression increased
during the transition in rCHO DP-12, while the same gene decreased in expression in
rCHO DHFR-. In total, the interaction test identified 2,956 genes that had significant
differences in expression patterns between rCHO DP-12 and CHO DHFR- when it
transitioned from 10% serum to 5% serum (FDR ≤ 0.01). The GO enrichment analysis
identified genes belonging to 12 categories to be enriched (Table 3.7). The GO terms that
were enriched among the interaction genes included DNA replication, cell cycle arrest,
protein transport, and cell redox homeostasis.
DNA replication term was represented by minichromosome complex maintenance
complex component 3 (Mcm3), nuclear factor I/A (Nfia), nuclear factor I/B (Nfib), DNA
polymerase alpha 2 (Pola2) and replication factor c5 (Rfc5) (Figure 3.9). The three genes
had either higher expression (Pola2, Rfc5) or did not significantly change (Mcm3) in
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rCHO DP-12, while the same genes had significantly lower expression (Mcm3, Pola2) or
did not increase in expression (Rfc5) in CHO DHFR- when they transitioned from 10% to
5% serum. The genes are involved in different aspects of DNA replication and cellular
proliferation such as initiation (Mcm3), elongation (Rfc5) and replication (Pola2).
Specifically, Mcm3 is a subunit of the MCM complex that are involved in the initiation
and regulation of DNA replication. The decrease in Mcm3 expression levels was
correlated with growth-arrest in human cell lines (Lee 2010). Rfc5 interacts with
proliferating cell nuclear antigen (PCNA) to form a complex that is required for
elongation by DNA polymerase delta and DNA polymerase epsilon. As noted earlier,
several genes related to oxidative stress were differentially expressed during the serumfree medium adaptation process. The cell cycle related genes were cyclin-dependent
kinase inhibitor 1a (Cdkn1a), senstrin 2 (Sesn2) and growth arrest specific (Gas2). The
difference in expression of Cdkn1a has already been discussed in the cell cycle genes
section. Sesn2 expression decreased in rCHO DP-12, while it remained the same in CHO
DHFR-. Increase in Sesn2 expression has been observed under oxidative stress. Gas2 had
an increase in expression rCHO DP-12, while the expression of Gas2 decreased in CHO
DHFR-. Jaluria et al. (2008) overexpressed Gas6 gene to successfully adapt the HEK-293
cells to serum-free medium. The cell redox homeostasis GO term further indicates the
differences in oxidative response between the two CHO cell lines. Specifically, the genes
belonging to thioredoxin family had difference in behavior between the two CHO cell
lines, in addition to the peroxidasin genes previously.
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The difference in expression of almost 3,000 genes between rCHO DP-12 and
CHO DHFR- during the transition from 10% serum to 5% serum further reinforces the
notion that each cell line responds in a unique manner to the serum-free medium
adaptation process. Further systems level analysis are required in addition to the work
here to completely characterize the serum-free medium adaptation process in CHO cells.
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Table 3.7 - Enriched GO terms among genes with expression differences between rCHO
DP-12 and CHO K1-PF during the transition from 10% serum to 5% serum

Go Term
ATP synthesis coupled
proton transport
Cell cycle arrest
Cell redox homeostasis
DNA replication
Glycolytic process
Metabolic process
Nucleotide-excision repair
Protein transport
Proteolysis involved in
cellular protein catabolic
process
Translation

p-value for
Overrepresentation

Number of
Genes in
Category
Effected

Number
of Genes
in
Category

GO:0015986
GO:0007050
GO:0045454
GO:0006260
GO:0006096
GO:0008152
GO:0006289
GO:0015031

0.01
0.05
0.03
0.05
0.03
0.01
0.02
0.03

10
5
10
13
6
87
5
32

32
12
34
40
15
383
10
146

GO:0051603
GO:0006412

0.04
0.00

5
57

18
158

Category
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Figure 3.9: Differences in expression DNA replication related genes between rCHO DP12 and CHO K1-PF. Abbreviations: Nfia – Nuclear factor I/A, Nfib – Nuclear factor I/B,
Pola2 – DNA Polymerase alpha 2, Rfc5 – Replication factor C5.
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3.5 Conclusions
Serum is an integral component of most primary animal cell culture medium. It
provides several nutrients such as growth factors, vitamins and trace elements; however,
it is undefined in nature and a potential source of contamination. In part due to these
disadvantages, the use of serum in industrial mammalian cell culture processes is highly
discouraged due to regulatory and contamination concerns. Hence, recombinant CHO cell
lines commonly undergo adaptation to the serum-free medium. In this study, two CHO
cell lines – a recombinant IgG1 producing rCHO DP-12 cell line and the non-recombinant
parental CHO DHFR- cell line, were attempted to be adapted to serum-free medium. As
has been reported in the literature and observed previously by our group with nonrecombinant CHO cell lines, the CHO DHFR- (non-recombinant) cell line was much
slower to adapt at every stage, and in this prescriptive adaptation approach, it failed to
progress beyond 5% serum medium. Conversely, rCHO DP-12 cell line adapted to
serum-free medium within 65 days, yet the rCHO DP-12 cells took the longest to adapt to
5% serum medium. In order to characterize this bottleneck point, RNA samples from
these two CHO cell lines representing different stages of the adaptation process were
sequenced using the next-generation RNA-Seq method. Serum sensitive genes that were
commonly affected between the two CHO cell lines were identified and used to analyze
the impact of serum-free medium adaptation process. Among the glycosylation genes,
sialidase 2 decreased in expression by over 300-fold throughout the adaptation process
and sialyltrasnferase (ST3Gal) genes were increased in expression, which correlates with
the previous observation in literature on increase in sialic acid residues when cells were
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cultured in serum-free medium. However, this was largely attributed to the decrease in
concentration of serum sialidases; but this study points out that the change occurs at gene
expression level too. Several cell cycle and apoptosis genes were sensitive to serum-free
medium adaptation process. Notably, cyclin-dependent kinase inhibitor 1a, Cdkn1a, had a
decrease in expression throughout the serum-free medium adaptation process in rCHO
DP-12. Among the apoptosis genes, an increase in expression of several pro-apoptotic
genes was such as Casp1 was observed and decrease in expression of anti-apoptotic
genes such as Birc3 was observed. This was particularly surprising as the RNA samples
were extracted from the mid-exponential growth phase during which the chances of
occurrence of apoptosis is minimal. A gene ontology enrichment analysis identified genes
related to oxidative stress enriched in both cell lines during the transition from 10%
serum to 5% serum. Several genes coding for antioxidant enzymes had increased
expression at 5% serum in comparison to the 10% serum, indicating that the cells might
be experiencing oxidative stress. The source of stress is likely due to the unregulated
uptake of iron, in the absence of transferrin in the serum-free medium. Additionally,
several genes families had differences in response between the two CHO cell lines during
the transition from 10% to 5% serum. Almost 3,000 genes had differences in behavior
between the two cell lines, indicating that the response of each cell line to serum-free
medium adaptation is unique. The GO categories enriched among these genes included
DNA replication, cell cycle genes, cell redox homeostasis and protein transport genes.
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CHAPTER FOUR
IMPACT OF LOW CULTURE TEMPERATURE AND LOW INITIAL MEDIA PH ON
CHINESE HAMSTER OVARY (CHO) CELL LINES: A TRANSCRIPTOMIC
PERSPECTIVE USING RNA-SEQ

4.1 Abstract
Recombinant protein therapeutics’ are increasingly administered in the treatment of
several life-threatening diseases including cancer. Chinese Hamster Ovary (CHO) cells
are an important biopharmaceutical cell line, used in the production of over 70% of the
approved protein therapeutics. However several limitations exist with the use of CHO
cell lines including low product titers/productivity. Often times, protein productivity and
culture longevity are improved by shifting to a lower process temperature. However the
exact mechanisms through which such manipulations impact the cells are currently
unknown. Transcriptomics is one such medium through which cellular mechanisms could
be better understood by measuring gene expression. Recently, CHO cell transcriptomics
has been encouraged with the establishment of Chinese hamster and CHO cell draft
genomes. In this study, comprehensive transcriptomic analysis using RNA-seq of two
CHO cell lines, a recombinant and a non-recombinant one, was performed to understand
and identify key CHO cell genes involved during the low temperature treatments (33°C).
Samples for RNA-seq were taken from the mid-exponential growth phase and sequenced
by HiSeq 2000. The sequenced sample contained over 15 million short reads, which were
assembled together with the CHO-K1 reference genome (v1.01). Comparison of the gene
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expression profiles of the CHO cell lines at 33°C and 37°C (control) revealed, in
common, 336 genes had higher expression and 39 genes had lower expression in the low
temperature culture (filter criteria were a minimum of two-fold expression change and
FDR ≤ 0.05). Genes such as Slc35d1 and Slc35d2, which are involved in the transport of
nucleotide sugars, were found to have higher expression at lower temperatures. This
could provide a possible explanation for the improvement in protein productivity
observed at low temperature treatments.
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4.2 Introduction
CHO cells are widely used in the biopharmaceutical industry, particularly in the
manufacture of recombinant therapeutics such as antibodies, interferons, blood factors
and growth factors(Butler and Meneses-Acosta 2012; Datta, et al. 2013; Kantardjieff and
Zhou 2013; Omasa, et al. 2010). It is estimated that more than 60% of the recombinant
protein therapeutics are produced using CHO cells, accounting for more than $100 billion
in global revenues(Bandaranayake and Almo 2013; Jayapal, et al. 2007; Kantardjieff and
Zhou 2013). Despite the availability of several mammalian cell line options, CHO cells
are selected for use due to several advantages over other cell lines, including easy scale
up to large-scale processes, well-developed transfection systems for easy recombinant
protein expression and the ability to perform compatible protein post-translational
modifications(Kim, et al. 2012; Omasa, et al. 2010; Wuest, et al. 2012).
In industry, it is a common practice to lower the culture temperature after an
initial growth phase in order to improve culture viability, as well as increase recombinant
protein yield and productivity relative to the original higher culture temperature(Fogolı́n,
et al. 2004; Fox, et al. 2004; Kaufmann, et al. 1999; Kou, et al. 2011; Trummer, et al.
2006; Yoon, et al. 2003a; Yoon, et al. 2003b). Unfortunately, the impact of reducing the
culture temperature on protein productivity is highly cell line and recombinant protein
specific. For example, several research groups have observed decreased or no change in
specific protein productivity after reducing the culture temperature for CHO cells and
other related mammalian cell lines (Yoon 2003antibody, Sureshkumar 1991, Barnabe
1994, Weidemann et al. 1994, Reuveny et al. 1986, Fox et al. 2004). In contrast, other
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research groups have reported substantial protein productivity improvements after
reducing the culture temperature(Fogolı́n, et al. 2004; Furukawa and Ohsuye 1998;
Kaufmann, et al. 1999; Yoon, et al. 2003b). Kantardjieff et al. (2010) used DNA
microarrays to assess gene expression changes in CHO cells under low temperature and
sodium butyrate treatment. They identified that cell cycle and growth factor related genes
had lower expression at low culture temperatures while extracellular matrix and fatty acid
metabolism genes had higher expression at the low culture temperatures. Unfortunately,
they used a proprietary DNA microarray in this study making it difficult to utilize these
findings, as the gene sequences were not made publicly available. As these previous
studies have identified a confounding effect of temperature and productivity.
Another important cell culture environmental factor that affects the protein
productivity is the culture pH. Specifically, CHO cells grown at low pH have been
improved cell viability, prolonged cultivation time and enhanced recombinant protein
yield (Trummer 2006, Yoon 2005, Miller 1988). Much of these improvements have been
attributed to decreased glucose consumption and lactate production rates (Yoon 2005).
Additionally, variations in pH can also influence glycosylation, a key post-translational
modification that influences protein efficacy (Borys 1993, Borys 1994, Yoon 2006,
Hayter 1993).
To further elucidate the mechanism of pH effect on glycosylation and other
culture parameters, transcriptome understanding of the pH influence on CHO cell culture
is necessary. Despite being one of the most basic and critical parameters, currently there
are no known transcriptome studies in literature understanding the response of CHO cells
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to extracellular pH variations. In this study, high-throughput, next-generation
transcriptomic technology, RNA-Seq, was utilized to understand the impact of
temperature and pH on two CHO cell lines– a recombinant CHO DP-12 cell line and a
non-recombinant CHO K1-PF cell line. The objective of the investigation was to shed
light on temperature and pH related effects, such as productivity improvements, high cell
viability and low waste production, by characterizing the impact on CHO cell
transcriptome.
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4.3 Materials and Methods
4.3.1 CHO Cell Lines
Two CHO cell lines were used in this study: 1) rCHO DP-12, clone #1934
(ATCC® CRL-12445™), a recombinant CHO cell line expressing a human monoclonal
antibody against Interluekin-8 (IL-8), and 2) CHO K1-PF (Sigma 00102307), a nonrecombinant CHO cell line derived from CHO-K1 and previously adapted to Sigma CHO
protein-free medium (TT Puck et al. 1958 Genetics of somatic cells III). The rCHO DP12 cell line was adapted to serum-free, protein-free, chemically defined CD CHO
medium (Life technologies, NY, USA) as described previously (Gowtham serum-free
adaptation). The CHO K1-PF cell line was also adapted to grow in CD CHO medium.
Anti-clumping agent (Life technologies, NY, USA) was added (1:250) to the medium to
prevent cell clumping in suspension cultures.

4.3.2 Culture Conditions
CHO cell cultures were seeded at ~ 9.0 X 104 cells/mL in 75 cm2 flasks (Corning
Inc, NY, USA) and grown in humidified incubators maintained at 37°C or 33°C with 5%
CO2 atmosphere. The initial culture pH measured in CD CHO medium in 5% CO2,
humidified incubator was 6.95 and no alterations were made to it. To assess the impact of
low pH on CHO cell transcriptome, the initial media pH was reduced to 6.70 using 1.2N
HCl (Thermo Fisher Scientific, NC, USA). CD CHO medium was supplemented with
5mM glutamine and anti-clumping agent (Life technologies, NY, USA) was added
(1:250). The initial pH and the pH the time of RNA extraction was measured using a
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Denver Instruments UltraBasic benchtop pH meter UB-10. Samples were taken every 24
hours for cell concentration and viability, glucose and lactate concentrations. Cell
concentrations and viabilities were measured using Bio-Rad TC20™ Automated Cell
Counter (Bio-Rad Laboratories, CA, USA). Glucose and lactate concentrations were
obtained using a Yellow Springs Instruments (YSI) 2900 Biochemistry Analyzer (Yellow
Springs, OH, USA). For each cell line, all four combinations of the two culture
temperatures (37°C or 33°C) and two initial culture pH values (6.95 and 6.70) were
examined. Duplicate cultures were conducted for all conditions examined. Statistical
analysis to find differences in growth rates was performed using JMP software (SAS
institute, NC, USA).

4.3.3 Transcriptome Analysis
For transcriptome analysis, RNA samples were extracted after the CHO cells
reached a minimum cell concentration (> 2.0 X 105 cells/mL). To collect mRNA samples,
RNAprotect® cell reagent (Qiagen, Valecia, CA) was added to a harvested sample
immediately upon withdrawal from the flask. Total RNA extraction was performed as per
RNeasy Plus Mini kit (Qiagen) protocol. Total RNA was extracted into 1.5 mL RNAaseFree, DNAase-Free tubes and stored in -80°C until required. A NanoDrop 8000 UV-Vis
spectrophotometer (Thermo Scientific, MA, USA) and Agilent 2100 Bioanalyzer System
(Agilent, Santa Clara, CA) with RNA 6000 Nano kit (Aglient) were used to confirm the
quality of the extracted total RNA samples. All samples had RNA integrity numbers
(RIN) values of greater than nine.
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4.3.4 Library Synthesis, Sequencing and Reference Mapping
The cDNA libraries for whole transcriptome sequencing for each sample were
constructed by following the recommended protocol of the TruSeq RNA sample
preparation v2.0 kit (Illumina, San Diego, CA). Briefly, messenger RNA (mRNA) was
enriched from total RNA using poly-T magnetic beads. Next, mRNA was cleaved into
fragments by a non-specfic RNA endonuclease and the fragmentation products were
synthesized into complementary DNA (cDNA) using reverse transcriptase and DNA
polymerase enzymes, respectively. The cDNA products then underwent an end repair
process to flush, A-tail, and phosphorylate the DNA ends. These products were then
ligated to adapters that serve as priming sites for enrichment by PCR to create the cDNA
libraries for sequencing. Each library contains an individual specific DNA index that is
used for multiplexing during massively parallel sequencing. The resulting cDNA libraries
were quality validated on an Agilent 2100 Bioanalyzer System to ensure proper fragment
distribution (~260 bp) and effective removal of adapter dimers. Sequence libraries were
multiplexed and sequence data collected on 2 lanes of a HiSeq 2500 (Illumina, San
Diego, CA) at the Genomics division of David H. Murdock Research Institute
(Kannapolis, NC) using a 2×101 bp, paired end read type. Raw sequence reads were
demultiplexed on the instrument and reads greater than or equal to 36 bp were cleaned of
adapter and low quality bases (less than Phred 15) with the Trimmomatic software
package (Bolger, et al. 2014).
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The trimmed reads obtained were mapped on to the Chinese hamster reference
genome sequence with the Subread Aligner (v1.4.5) (Liao, et al. 2013b). Subread
performed local alignment of the reads and reported the locations that have the largest
overlap among the reads. FeatureCounts was used to assign the reads to the target genes
and summarize the data into a read counts table (Liao, et al. 2013a). This table was
subsequently used as input in the differential gene expression analysis.

4.3.5 Differential Gene Expression Analysis and Gene Ontology Analysis
Differential gene expression analysis of the RNA-Seq data used the edgeR
software package for data filtering and statistical analysis (Robinson, et al. 2010). The
software edgeR utilizes a negative binomial distribution model to capture the quadratic
mean-variance relationship common to RNA-Seq data (Chen, et al. 2014; Robinson and
Smyth 2008). Additionally, edgeR employs an empirical Bayes method to stabilize overdispersion across genes by sharing information across all observations including
replicates (McCarthy, et al. 2012; Robinson and Smyth 2007; Robinson, et al. 2010). The
steps used for RNA-Seq statistical analysis were a) filtering low expressed genes, b)
normalizing the library, c) plotting the multidimensional scaling graph, d) identifying
differentially expressed genes using generalized linear model and e) analyzing genes for
overrepresentation by gene ontology (GO) using GOseq. The raw data was mapped to
27,629 genes in the Chinese hamster reference genome (Lewis et al.). An independent
gene filtering criteria of 10 count-per-million (cpm) in at least two samples was used to
remove genes with low expression (Anders, et al. 2013). The library sizes for all samples

86

were normalized using trimmed mean of M-values (TMM) method in edgeR (Robinson
and Oshlack 2010). Multidimensional scaling (MDS) plot was used to visualize the
similarities and dissimilarities between the replicates and samples (Appendix B.2, B.3).
Additionally an estimation of tagwise dispersion related to the design matrix was
conducted using the quantile-adjusted conditional maximum likelihood (qCML) method
(McCarthy, et al. 2012). To identify the differentially expressed genes, one-way layout
was used for pairwise comparisons between the different conditions. A BenjaminiHochberg procedure was used to control for false discovery rates (FDR) and FDR ≤ 0.01
was used, unless otherwise specified (Benjamini and Hochberg 1995). The differentially
expressed genes were used for gene ontology enrichment analysis using the goseq
software – a R based Bioconductor package (Young, et al. 2012). GOseq accounts for
selection bias for long and overexpressed gene sequences by calculating the Probability
Weighting Function (PWF) (Oshlack and Wakefield 2009). For GO analysis, goseq uses
two vectors – one containing all the measured genes and the other containing the
differentially expressed genes. Additional information containing genes length and the
GO categories associated with the genes were supplied. GO terms with p ≤ 0.05 from the
over-representation test were considered to be statistically significant. Additionally,
manual screening of gene and gene families, that had common stem in its gene symbol,
with greater than 1.5-fold expression change was performed to identify genes sensitive to
serum-free medium adaptation process.
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4.4 Results and Discussion
The effects of temperature and pH on protein productivity proved to be cell line
and recombinant protein specific. In order to address this potential issue, two CHO cell
lines were used. In order to isolate the temperature and pH effect on gene expression, two
CHO cell lines used were a recombinant CHO cell line (rCHO DP-12) and a nonrecombinant cell line (CHO K1-PF). CHO K1-PF represents a parental cell line of rCHO
DP-12; however these cell lines have been separated for a couple decades (Hamillton and
ham, et al. 1998). CHO K1-PF was adapted to serum-free medium by Hamilton and ham
et al. (1978) and then to CD CHO medium for this study. While the rCHO DP-12 cell
lines was adapted to serum-free, protein-free CD CHO medium in a previous study
(Gowtham et al. 2016). Thus, both CHO cell lines were cultured in the same chemically
defined, protein-free, serum-free medium (CD CHO medium). The two CHO cell lines
were cultivated at two culture temperatures – control (37°C) and low (33°C)
temperatures, and the two initial media pH – control pH (6.95) and low pH (6.70). The
study consisted of a full factorial model of three factors with two levels each resulting in
eight different conditions. The cells were seeded at very low cell concentrations, such
that the pH did not significantly change during the course of the experiment.
Additionally, the utilization of the low cell concentrations minimized the glucose and
waste product concentration changes over the course of the experiment.
Figure 1 shows the growth profiles for all the rCHO DP-12 and CHO K1-PF
cultures. As expected, the 37°C cultures had significantly higher growth rates than the
33°C cultures (P ≤ 0.05) (Table 1). The rCHO DP-12 had slightly higher growth rates for
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conditions compared to the CHO K1-PF (P ≤ 0.05). Unexpectedly, the growth rates were
not affected with respect to culture pH for both CHO cell lines (P ≤ 0.05). Figure 2 shows
the glucose and lactate concentrations profiles for both cell lines. The glucose
concentrations are nearly unchanged up to the time of RNA harvesting. The lactate
concentration at the time of the RNA harvest is very low, less than 4mM for all samples.
As expected, the low pH culture have lower lactate accumulation relative to the normal
pH culture for both cell lines at both 37°C and 33°C.
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Table 4.1 - Growth rates for all rCHO DP-12 and CHO K1-PF cultures grown at different culture
temperature and different initial media pH. Errors represent 95% confidence intervals.
Cell Lines
rCHO DP-12
CHO K1-PF

pH
Control pH
Low pH
Control pH
Low pH

Temperature
37°C
0.035 ± 0.001
0.034 ± 0.001
0.029 ± 0.001
0.029 ± 0.001
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33°C

0.016 ± 0.001
0.014 ± 0.001
0.010 ± 0.001
0.01 ± 0.001

A

B

Figure 4.1: Growth profiles for rCHO DP-12 and CHO K1-PF cultures at low
temperature and low pH conditions. A) rCHO DP-12 and B) CHO K1-PF were grown at
37°C (circles) and 33°C (squares) and pH 6.95 (closed) and pH 6.70 (open). Black circles
indicate the time at which RNA samples were harvested.
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DP-12

K1-PF

DP-12

K1-PF

Figure 4.2: Glucose and lactate concentration profiles for rCHO DP-12 and CHO K1-PF
cultures. Glucose (Top) consumption profiles and lactate (bottom) production profiles are
shown for rCHO DP-12 (left) and CHO K1-PF (right) grown at 37°C (circles) and 33°C
(squares) and pH 6.95 (closed) and pH 6.70 (open). Black circles indicate the time at
which RNA samples were harvested.

92

4.4.1 Transcriptome analysis of CHO cell lines
RNA samples were extracted from the both CHO cell lines at a minimum of 2 X
105 cells/mL concentration and > 95% viability, at the time points indicated by arrows in
Figure 1. At the time the RNA samples were taken, the glucose concentration for all
cultures was above 30 mM and the lactate concentrations were below 4 mM, indicating
the cells had sufficient glucose and the cultures were not lactate inhibited (Lu, et al.
2005). The cultures continued past the RNA harvest time point to demonstrate that all
cultures were in mid-exponential growth phase. The libraries for both replicates of CHO
K1-PF cells grown at 37°C and 6.70 pH was lost due to contamination and were not used
in the statistical analysis. Due to the unbalanced nature of the data, a one-way layout was
used for the differential gene expression analysis. The number of differentially expressed
genes in all pairwise comparisons performed between rCHO DP-12 and CHO K1-PF
cultures are shown in Table 2 (FDR ≤ 0.01). The pairwise comparisons with pH as the
main effect had consistently much lower number of significant genes for both CHO cell
lines than the comparisons with temperature or cell lines as the main factors. Specifically,
the comparison of low pH and control pH cultures for rCHO DP-12 cells and CHO K1PF cells at 33°C resulted in 21 genes and 28 genes with differential expression,
respectively. Furthermore, the number of differentially expressed genes in these
comparisons is much lower than the number of false positive genes expected in a
comparison involving 11,000 genes at FDR ≤ 0.01. Due to the minimal impact of pH on
the transcriptomes of rCHO DP-12 and CHO K1-PF in this study, a new model with only
cell line and temperature as the two factors was subsequently used. The pairwise
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comparisons for rCHO DP-12 and CHO K1-PF using the new two-factor model are
shown in Table 3 (FDR ≤ 0.01). The pairwise comparisons with temperature as the main
effect for rCHO DP-12 and CHO K1-PF were used to assess the impact of temperature
on CHO cell transcriptome. Around 4,500 genes in rCHO DP-12 and around 5,000 genes
in CHO K1-PF were sensitive to the changes in culture temperature. The overlap of the
3,186 differentially expressed genes in rCHO DP-12 and CHO K1-PF was used for
further analysis. Specifically, 1,719 genes with higher expressed and 1,467 genes with
lower expression were commonly affected by temperature in the two CHO cell lines
(Figure 4.3). These common genes were used for further analysis of the impact of
temperature on functional groups such as glycosylation, apoptosis, and cell cycle, in
addition to gene ontology enrichment analysis.
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Figure 4.3: Temperature sensitive genes for rCHO DP-12 and CHO DHFR- were 4565
and 5222 genes, respectively. Temperature sensitive genes that had A) higher expression
and B) lower expression temperature sensitive genes between rCHO DP-12 and CHO
DHFR-
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Table 4.2 - Pairwise comparisons of rCHO DP-12 and CHO K1-PF cultured at different temperatures and initial media pH
(FDR ≤ 0.01). There were 11,016 genes using for the comparison. Numbers in parenthesis indicated the number of genes with
greater than 1.5-fold change in expression
Cell
Lines

rCHO DP-12
Temperature

37°C
rCHO
DP-12
33°C

37°C
CHO
K1-PF
33°C

pH
Control
pH
Low pH
Control
pH

37°C
Control
Low
pH
pH
151
(39)

CHO K1-PF

33°C
Control
Low
pH
pH
3176
3669
(1091) (1303)
3149
3380
(1072) (1149)
21 (14)

Low pH
Control
pH
Low pH
Control
pH
Low pH

37°C
Control
Low
pH
pH
6157
(3405)
6170
(3361)
6650
(3929)
6697
(3895)

33°C
Control
pH
Low pH
7101
7246
(4408)
(4625)
7083
7235
(4378)
(4578)
6221
6374
(3426)
(3642)
6214
6251
(3214)
(3521)
4637
5271
(1985)
(2497)
28
(14)
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Table 4.3 - Pairwise comparisons of rCHO DP-12 and CHO K1-PF cultured at different
temperatures (FDR ≤ 0.01). There were 11,016 genes using for the comparison. Numbers in
parenthesis indicated the number of genes with greater than 1.5-fold change in expression. The
numbers in bold represent comparisons with temperature as the main factor and the numbers
in italics represent comparisons with cell line as the main factor.
Cell Lines

rCHO DP-12
Temperature

37°C

33°C
4565
(1045)

37°C
rCHO DP-12
33°C
CHO K1-PF

37°C
33°C
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CHO K1-PF
37°C
6420
(3340)
6909
(3767)

33°C
8043
(4474)
7280
(3461)
5222
(2186)

4.4.2 Impact of low temperature on glycosylation related genes
Glycosylation is a critical post-translational modification involving the addition of
carbohydrate moieties on the nascent protein inside the Golgi apparatus. For therapeutic
proteins, glycosylation is often critical to determining efficacy, immunogenicity, and
stability of the protein (Walsh et al. 2004). In biopharmaceutical industry, obtaining a
consistent glycosylation profiles is necessary for regulatory approval. Factors that change
glycosylation related gene expression would most likely impact protein glycosylation. In
this study, the impact of culture temperature on glycosylation was investigated by
characterizing gene expression changes for the 300 glycosylation-related genes. The
initial glycosylation list of 298 genes was obtained from Xu et al. The gene list was
compared with the temperature sensitive genes in rCHO DP-12 and CHO K1-PF.
However, it was noticed that 34 glycosylation genes from Xu et al. did not map to the
Chinese hamster reference genome. The Ensemble gene IDs corresponding to the
unmapped genes were used to investigate the identity of these genes in Chinese hamster
genome. Using the Ensemble IDs, the nucleotide sequence was obtained and used in
CHOblast search tool (www.chogenome.org) against CH_RefSeq_2014 database to find
the positioning of the unmapped genes on the Chinese hamster genome scaffolds. The
position coordinates were used in the Chinese hamster genome viewer to visualize the
gene (www.chogenome.org). Several genes were labeled as LOCs genes, indicating that
these genes are not functionally characterized. The corrected glycosylation list containing
264 genes is provided in the supplementary. Additionally, few genes names were also
updated. Of the 264 genes, 62 glycosylation genes were sensitive to temperature in both
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rCHO DP-12 and CHO K1-PF. The majority (> 80%) of these genes had an increase in
expression in both CHO cells cultured at low temperature. Many of the gene expression
changes were very small change and likely had little effect on the overall protein
glycosylation. If just the genes that changed more than 1.5-fold in expression were
examined, several important protein glycosylation genes had differential expression;
specifically Neuaminidase genes – Neu1 and Neu2, and nucleotide sugar transporters
Slc35d1 and Slc35d2 (Table 4). The fold changes of the genes due to temperature are
shown in Figure 4.4 and 4.5. Neu1 and Neu2 are two of the four characterized
mammalian sialidases, which catalyze the removal of sialic acids from glycoproteins
(Miyagi and Yamaguchi 2012). Neu2 expression was lower, while Neu1 expression was
higher for the 33°C culture relative to the 37°C culture for both CHO cell lines.
Interestingly, the baseline Neu1 expression is much higher than Neu2 in both cell lines.
The higher expression of Neu1 is likely to result in the overall increase in sialidase
enzyme activity and greater degradation of sialic acid at lower culture temperature.
Moreover, Neu3 had a significant increase in expression in CHO K1-PF but not in rCHO
DP-12 (FDR ≤ 0.01). In IgG-based therapeutics, the presence of terminal sialic acids on
the glycosylated protein has been observed to reduce antibody-dependent cellular
cytotoxicity (ADCC) and mediate anti-inflammatory response(Costa, et al. 2013).
Slc35d1 and Slc35d2 encode nucleotide sugar transporter proteins that are used to
transport nucleotide sugars from cytosol into the endoplasmic reticulum (ER) and Golgi
apparatus. Specifically, Slc35d1 transports UDP-glucuronic acid (UDP-GlcA) and UDPN-Acetylgalactosamine (UDP-GalNAc), while Slc35d2 transports UDP-N-
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Acetylglucosamine (UDP-GlcNAc). Slc35d1 and Slc35d2 had increase in expression of
over 2-fold at lower temperature for both CHO cell lines. The overexpression of Slc35d1
in yeast cells resulted in increased in the translocation of UDP-GlcA and UDP-GalNAc
in to the ER (Muraoka, et al. 2001). The core glycan structure in N-linked glycosylation
is made up of two N-acetylglucosamine. Additionally, the complex type of N-glycans
contains one or two more N-acetylglucoseamine in its structure. The increase in
nucleotide sugar transporters in the ER/Golgi can directly improve the availability of the
critical sugar residue, N-acetylglucoseamine, and thereby improving protein
glycosylation.
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Table 4.4 - Glycosylation genes that were temperature sensitive with more than 1.5-fold
change in both rCHO DP-12 and CHO K1-PF (FDR ≤ 0.01)
Fold Change
Gene
Symbol
ARSA
Csgalnact2
EXTL1
UGGT2
UGCG
IDUA
NAGA
CTBS
GBA
MAN2B1
ALG9
SLC35D1
SLC35D2
TSTA3
UAP1
Neu1
Neu2
SULF2

Gene Family
Arylsulfatases
GalNAc-transferases
GlcNAc-transferases
Glucosyltransferases
Glucosyltransferases
Iduronidases
Lysosomal Enzymes
Lysosomal Enzymes
Lysosomal Enzymes
Mannosidase
Mannosyltransferases
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nucleotide Synthesis
Nucleotide Synthesis
Sialidases
Sialidases
Sulfatases

rCHO DP-12
1.5
1.5
2.0
2.0
1.6
1.9
1.7
1.5
1.5
1.5
1.6
2.1
2.0
1.6
-1.5
1.8
-3.5
3.2
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CHO K1-PF
2.4
1.6
1.8
2.1
2.1
2.5
1.7
2.0
2.2
1.7
1.8
2.0
3.4
2.1
-1.6
2.6
-3.0
91.4

Figure 4.4: Temperature sensitive glycosylation related genes. Normalized expression
levels of sialidase genes – Neu1, Neu2 and Neu3 in rCHO DP-12 and CHO K1-PF
cultured at 33°C and 37°C. Neu3 had no significant change in expression in rCHO DP12, as indicated by #.
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A

B

Figure 4.5: Temperature sensitive glycosylation related genes. Normalized expression
levels of Nucleotide sugar transporters A) Slc35d1 and B) Slc35d2 in rCHO DP-12 and
CHO K1-PF cultured at 33°C and 37°C.
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4.4.3 Impact of low temperature on cell cycle genes
Cell cycle genes that belonged to various cell cycle phases such as G-phase, Mphase, S-phase and DNA replication genes, as well as regulation related genes such as
cell cycle checkpoint, cell cycle arrest and progression of cell cycle were examined. In
this study, the temperature sensitive genes were compared to 84 cell cycle related genes
that were compiled by SABiosciences (Fischer, et al. 2011; Montes, et al. 2011; Wu, et
al. 2011). Of the 84 cell cycle genes, there were 11 temperature sensitive genes that had
more than 1.5-fold change in expression (Table 5). The temperature sensitive genes
included cyclin-dependent kinase inhibitors (Cdkn1a, Cdkn3), cyclins (Ccna2, Ccnb1)
and mini chromosome maintenance gene (Mcm3) (Figure 4.6). Cyclin-dependent kinase
inhibitor genes encode for proteins that bind to and inhibit the activity of cyclin-cylindependent kinases complexes, thereby inhibiting cellular proliferation. Interestingly,
cyclin-dependent kinase inhibitor, Cdkn3, had a decrease in expression at lower culture
temperature in both rCHO DP-12 and CHO DHFR-. In contrasts, Cdkn1a had over twofold increase in expression at lower culture temperature in both CHO cells, indicating that
the cellular proliferation was inhibited at lower temperature primarily through Cdkn1a.
Cyclins, Ccna2 and Ccnb1, which are essential for the cell cycle progression from G1/S
phase and G2/M phase, had a decrease in expression at 33°C relative to 37°C; further
contributing towards slow growth rates at low culture temperature. The results are
consistent with the observations of Moore et al. (1997) who observed an increase in
proportion of cells in G1 phase when the culture temperatures were shifted.
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Table 4.5 - Cell cycle genes with more than 1.5-fold change that were temperature
sensitive in both rCHO DP-12 and CHO K1-PF
Fold Change
rCHO DP- CHO K112
PF

Gene
symbol

Gene name

Aurka
Aurkb

aurora kinase A
aurora kinase B, transcript variant X2

Casp3

Caspase 3

Ccna2
Ccnb1
Cdc6
Cdkn1a

cyclin A2
cyclin B1, transcript variant X2
Cell division cycle 6
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
cyclin-dependent kinase inhibitor 3, transcript
variant X4
minichromosome maintenance complex
component 3, transcript variant X2
MDM2 oncogene, E3 ubiquitin protein ligase,
transcript variant X1
protein phosphatase, Mg2+/Mn2+ dependent, 1D,
transcript variant X2

Cdkn3
Mcm3
Mdm2
Ppm1d
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-1.6
-1.5

-2.2
-2.7

2.0

1.8

-1.5
-1.7
-1.7
4.1

-2.5
-2.4
-2.3
4.3

-1.7

-2.7

-1.5

-1.8

2.1

2.5

1.6

1.7

Figure 4.6: Temperature sensitive cell cycle related genes. A) Cyclin-dependent kinase
inhibitors and B) Cyclins represent the temperature sensitive cell cycle genes in both
CHO cell lines.
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4.4.4 Impact of temperature on apoptosis-related genes
As mentioned earlier, one of the major reasons to culture CHO cells under low
temperature condition is to delay the onset of apoptosis and consequently prolong culture
duration. Apoptosis generally occurs through two different pathways – an extrinsic
pathway (death receptor) or an intrinsic pathway (mitochondria-mediated) (Arden and
Betenbaugh 2004; Miura, et al. 2012; Wong, et al. 2006). To investigate the impact of
low temperature on apoptosis, the genes that were commonly affected in both CHO cells
were compared to the 84 apoptosis pathway related genes compiled by SABiosciences
(Dutta et al. 2012, Mao et al. 2010, Ripka et al. 2010). Of the 84 apoptosis related genes,
there were nine temperature sensitive genes with greater than 1.5-fold change in
expression (Table 4.6). All the nine genes had increase in expression in both rCHO DP12 and CHO DHFR- at lower culture temperature relative to the control culture
temperature. Interestingly, the nine genes consisted of several apoptotic genes such as
caspase 3 (Casp3), caspase 6 (Casp6), and Bcl2-associated X protein (Bax), and a few
anti-apoptotic genes such as nuclear protein 3 (Nol3) and activating transcription factor 5
(Atf5). Caspases - Casp3 and Casp6 are known as executor caspases, that function in the
final steps of apoptosis to complete cell death. Nol3 is an anti-apoptosis protein that has
been shown to down-regulate the enzyme activities of caspases including caspase 8.
Interestingly, Casp8, one of the initiators of apoptotic cell death, had a decrease in
expression at lower culture temperature in both CHO cells. The observed levels of
expression of pro-apoptosis/anti-apoptosis proteins may not necessarily be enough to
exert an influence on apoptosis. The samples for RNA were harvested from the mid-
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exponential growth phase; however the occurrence of apoptosis is generally observed at a
much later phase in the process.
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Table 4.6 - Apoptosis genes with more than 1.5-fold change that were temperature
sensitive in both rCHO DP-12 and CHO K1-PF
Fold Change
Gene
symbol
Apaf1
Atf5
Bax
Bcl2l11
Casp3
Casp6
Dapk1
Fas
Nol3

Gene Description
rCHO DP-12 CHO K1-PF
apoptotic peptidase activating factor 1,
transcript variant X3
2.0
2.6
activating transcription factor 5,
transcript variant X2
2.5
2.1
BCL2-Associated X Protein
2.2
2.2
BCL2-like 11 (apoptosis facilitator),
transcript variant X1
1.8
1.9
Caspase 3
2.0
1.8
caspase 6, apoptosis-related cysteine
peptidase, transcript variant X2
1.8
2.5
death-associated protein kinase 1,
transcript variant X2
1.8
3.2
Fas cell surface death receptor,
transcript variant X4
1.7
2.5
nucleolar protein 3 (apoptosis repressor
with CARD domain), transcript variant X1
1.5
1.9
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4.4.5 Gene ontology enrichment analysis
To further understand the cellular changes occurring in CHO cells due to culture
temperature, a gene ontology (GO) enrichment analysis by GOseq bioconductor package
was used to identify enriched GO terms (Young, et al. 2012). The GO analysis was
performed for 1,479 genes with GO terms associated out of the 3186 genes. GO terms
with 5 or more genes in category were considered as the major GO terms. The
significantly enriched GO terms included DNA replication, cellular protein metabolic
process, translation initiation, regulation of apoptotic process and metabolic processes (p
≤ 0.05) (Table 4.7).
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Table 4.7 - Enriched GO terms among the common temperature sensitive genes in rCHO
DP-12 and CHO K1-PF (FDR ≤ 0.01)
p-value for
Overrepresentation

Number of
Number of
Genes in
Genes in
Category
Category
Effected
6
12

Go Term

Category

Cellular process
Cellular protein
metabolic process
Chromatin assembly or
disassembly
DNA metabolic process
DNA repair
DNA replication
Metabolic process
Nucleobase-containing
compound metabolic
process
Regulation of apoptotic
process
Translational initiation

GO:0009987

0.019

GO:0044267

0.000

10

14

GO:0006333
GO:0006259
GO:0006281
GO:0006260
GO:0008152

0.003
0.037
0.002
0.010
0.035

10
6
16
15
85

20
14
41
40
383

GO:0006139

0.034

10

28

GO:0042981
GO:0006413

0.032
0.013

9
6

26
15
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The majority of the enriched DNA replication, cellular protein metabolic process
and translation initiation genes had lower expression at 33°C relative to 37°C in both
CHO cells. There were 15 DNA replication genes enriched, with 13 of the 15 genes had
lower expression in both CHO cells cultured at 33°C. Five of the 15 genes had over 1.5fold change in expression at lower temperature in both CHO cell lines – Mcm3, Mcm5,
Pold1, Pold2, and Polq. DNA polymerases play critical roles in synthesizing DNA, DNA
repair, DNA recombination and bypassing DNA damage. The classical eukaryote DNA
polymerases –polymerase delta (Pold1, Pold2), which belong to the family B
polymerases, are involved with nuclear DNA replication(Hübscher, et al. 2002).
Polymerase theta (Polq) is a novel DNA polymerase that belongs to family A
polymerases. Polymerase theta is hypothesized to play a role in DNA repair of interstrand cross-links, but the mechanism is not clearly known (Hübscher, et al. 2002). The
decrease in the expression of DNA polymerases and mini-chromosome complexes genes
in 33°C cultures compared to 37°C cultures can be related to the observed decrease in
cell proliferation and growth rate at 33°C cultures. Other GO terms enriched included
translation and cellular protein metabolic process. There were 6 translation genes that
were enriched, out of which 5 translation genes had lower expression in both cell lines at
33°C relative to 37°C. Additionally, 9 of the 10 cellular protein metabolic process genes
had lower expression. The genes belonged to the TCP1 complex and a heat shock protein
60, Hspd1 gene, was also included. These genes are involved in the protein folding
machinery of ER. The decrease in the expression of translation initiation genes and the
protein folding genes enriched among the cellular protein metabolic process is directly
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related to the decrease in global protein synthesis observed for CHO cells cultured at low
temperature (Masterton and Smales 2014).
The majority of the genes, six out of nine, belonging regulation of apoptosis GO
term had higher expression at 33°C relative to 37°C in both CHO cells. Interestingly,
several of these genes were pro-apoptotic genes such as Bcl2l1, Bcl2l2, Nod1 and Nod2 –
all of which had increase in expression at 33°C relative to 37°C. These enriched proapoptosis genes could play a critical role in the observed delay in the onset of apoptosis
under low temperature cultivation (Kaufmann, et al. 1999; Moore, et al. 1997; Trummer,
et al. 2006). Through the GO enrichment analysis, genes that were enriched among the
common temperature sensitive genes in rCHO DP-12 and CHO K1-PF were identified.
Through the enriched GO terms, several genes related to critical processes such as
apoptosis, protein folding, translation and DNA replication were identified. These genes
could serve as targets for transferring the benefits of low culture temperature cultivation
to control culture conditions.
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4.5 Conclusions
Temperature and pH are two important process parameters that are closely
monitored and maintained for a successful CHO cell culture. In biopharmaceutical
industries, lower culture temperatures have been applied in order to improve recombinant
protein productivity and protein quality. The impact of low temperature has been highly
variable and sometimes, dependent on the CHO cell line used. Similarly, low culture pH
has been observed to reduce toxic metabolite build-up and improve protein expression
rates. In this study, a whole-transcriptome sequencing was performed using RNA-Seq on
two CHO cell lines, rCHO DP-12 and CHO K1-PF, to observed the impact of low
temperature and pH. The initial pairwise comparisons indicated that the differences in
gene expression due to pH were minimal and confounded with type-I error. Due to the
minimal impact of pH on CHO cell transcriptome in this study, the RNA-Seq analysis
was performed with temperature and cell type as the two factors. In total, there were
3,186 common genes that were temperature sensitive in both rCHO DP-12 and CHO K1PF. The common gene list was used for functional analysis of gene such as glycosylation,
apoptosis and cell cycle genes. Glycosylation genes that were commonly impacted by
temperature in both CHO cell lines were Neuraminidase 2 (Neu2), Solute carrier family
35 members - d1 (Slc35d1) and d2 (Slc35d2). The decrease in Neu2 expression could
decrease the susceptibility of glycoprotein degradation by sialidases, which could benefit
IgG based anti-inflammatory therapeutics. Slc35d1 transports UDP-glucuronic acid
(UDP-GlcA) and UDP-N-Acetylgalactosamine (UDP-GalNAc), while Slc35d2 is known
to transport UDP-N-Acetylglucosamine (UDP-GlcNAc). The increase in nucleotide sugar
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substrates in the ER/Golgi can directly improve protein glycosylation. Among the cell
cycle genes, higher expression of cyclin-dependent kinase inhibitor 1a and lower
expression of cyclins Ccna2 and Ccnb1 could be key genes involved in the observed slow
growth rates and cellular proliferation at low temperatures. GO terms related to key
biological processes such as DNA replication, protein metabolic processes, translation
and regulation of apoptosis were found to be enriched among the temperature sensitive
genes. Genes representing DNA replication and translation had lower expression in both
CHO cell lines cultured at 33°C relative to 37°C, these genes represent the decrease in
cellular proliferation and global protein synthesis observed at low temperatures. Several
pro-apoptotic genes such as Bcl2l1 and Bcl2l2 had increase in expression in CHO cells
cultured at low temperatures. These genes might be critical in improving the apoptotic
resistance of CHO cells under low temperatures. Overall, the gene expression profiles of
rCHO DP-12 and CHO K1-PF was characterized to understand the impact of temperature
at the gene expression level.
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CHAPTER FIVE
ASSESSING THE IMPACT OF EXCESSIVE MEDIA GLUCOSE
CONCENTRATIONS ON RECOMBINANT CHINESE HAMSTER OVARY (CHO)
CELL TRANSCRIPTOME USING RNA-SEQ

5.1 Abstract
Chinese hamster ovary (CHO) cells have been used for over 25 years in the
biopharmaceutical industry to produce recombinant therapeutics, where CHO cells
produce almost one in three of the manufactured recombinant therapeutics. CHO cells
offer several advantages over other cell lines, yet the protein titers are only 5-10 g/L,
leading to high market prices. A limited system-level understanding of CHO cells and the
effects of process variables on these cells hinder productivity enhancement efforts. The
recent establishment of genomes sequences for CHO-K1 cell line and Chinese hamster
organism provide sound platforms to support ‘omics based studies, such as
transcriptomics. The information obtained from comprehensive transcriptome analysis
can be leveraged to engineer CHO cells with desired phenotypes including high protein
titers and used to control the bioreactor environment to reduce waste production. For
most mammalian cell lines, glucose serves as the primary carbon source required for
growth and maintenance. Glucose metabolism is also central to several key intermediates
for the synthesis of cellular components such as lipids, sugar chains and nucleic acids are
generated during glycolysis. However, incomplete oxidation of glucose can lead to
lactate production and inefficient low energy. Typically, mammalian cell culture media
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contain high glucose concentrations that are analogous to diabetic levels of glucose in
humans, suggesting that the mammalian cells are cultivated in excess glucose.
Alternatively, maintaining low glucose concentrations (5 mM -10 mM) has been
attempted to reduce the glucose intake by mammalian cells. The effects of extracellular
glucose concentration (30 mM or 10 mM) on the transcriptome of rCHO DP-12 cells
producing monoclonal antibody were investigated. Only 575 genes were identified as
significantly different (FDR ≤ 0.01). Moreover, gene expression analysis revealed that no
notable changes in glycolysis, TCA cycle or glycosylation genes were observed in CHO
cell cultured under different glucose concentrations. These expression studies indicated
that low glucose concentration batch medium for fed-batch CHO cell cultures has
potential to improve processes by reducing waste accumulation without impacting
process related genes.
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5.2 Introduction
CHO cells are widely used in the biopharmaceutical industry, particularly in the
manufacture of several recombinant protein therapeutics including antibodies,
interferons, blood factors and growth factors (Butler and Meneses-Acosta 2012; Datta, et
al. 2013; Kantardjieff and Zhou 2013; Omasa, et al. 2010). It is estimated that more than
60% of the recombinant protein therapeutics are manufactured using CHO cells,
accounting for more than $100 billion in global revenues (Bandaranayake and Almo
2013; Jayapal, et al. 2007; Kantardjieff and Zhou 2013). Despite the availability of
several mammalian cell line options, the selection of CHO cells as production host is due
to several advantages offered by it including easy scale up to large-scale processes, welldeveloped transfection systems for easy recombinant protein expression and the ability to
produce human-compatible proteins with proper post-translational modifications (Kim, et
al. 2012; Omasa, et al. 2010; Wuest, et al. 2012).
For most mammalian cell lines, glucose serves as the primary carbon source
required for growth and cell maintenance. Additionally, glucose metabolism is central to
several key intermediates for the synthesis of cellular components such as amino acids,
fatty acids, and nucleic acids (Ozturk and Hu 2005). Typically, mammalian cell culture
media contains glucose concentrations ranging from 25 mM to 35 mM glucose (~4.5 g/L
to 6.5 g/L). The medial glucose concentrations above 10 mM glucose are analogous to
diabetic levels of glucose in humans, suggesting that most mammalian cell cultures
experience high glucose exposure (American Diabetes Association 2008). Glucose
concentrations have been reported to affect several aspects of cell culture including
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growth rates, glucose consumption rate and oxygen uptake rate (Lee et al., Meuwly et al,
Lu et al.). CHO cell metabolism under high glucose concentrations is characterized by
high glucose uptake rates, followed by incomplete oxidation leading to high lactate
secretion even in the presence of plentiful of oxygen; a phenomenon known as Warburg
effect/aerobic glycolysis (Mulukutla et al., Neerman 1996, Lao 1997). Lactate, which is
considered a metabolic waste by-product, has long been observed to have adverse effects
on mammalian cell growth, protein production and quality (Lao 1997, Ozturk 1992, Hu
1987, Omasa 1992). Additionally, it has been recently observed that chronic exposure to
high glucose concentrations has been observed to alter expression in genes related to
apoptosis, cellular organization and signal transduction in insulin-producing mouse
embryonic stem cells (Yee et al. 2012). Several approaches to limit lactate production
have included substituting glucose with alternate carbon sources such as galactose or
applying a sophisticated glucose feeding mechanism based on pH measurements
(Altamirano 2000, 2006, Gagnon et al.). Alternatively, maintaining low glucose
concentrations (~ 5mM) has been attempted through programmed feeding or fed-batch
cultures to effectively reduce the glucose intake by mammalian cells and subsequently
lowering lactate production (Hayter 1992, Hu et al. 1988, Zhou et al. 1995). Moreover in
a separate study, low glucose concentrations (~1 mM or above) exerted little change on
CHO cell intracellular metabolites including ATP levels, amino acids and organic acids
involved in TCA cycle (Lu, et al. 2005). However, understanding gene expression
changes in CHO cells at low glucose concentrations is necessary to optimize and control
the process.
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In this study, the impact of the extracellular glucose concentration on the CHO
cell transcriptome was investigated using next-generation transcriptomic technique RNASeq. The recombinant CHO cell line, rCHO DP-12, was used that produces a monoclonal
antibody IgG1 against interleukin-8. Transcriptome profiles of rCHO DP-12 cells cultured
at two initial glucose concentrations – 30 mM glucose and 10 mM glucose were
compared representing the higher and low glucose concentrations respectively.
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5.3 Materials and Methods
5.3.1 CHO Cell Line and Culture Conditions
rCHO DP-12, clone #1934 (ATCC® CRL-12445™) cells were purchased from the
American Type Culture Collection (ATCC). The rCHO DP-12 cells express a human
monoclonal antibody (IgG1) against Interluekin-8 (IL-8). The CHO cells were grown in a
mixture of 80% DMEM, with no added glucose (Life technologies, NY, USA) and 20%
CD CHO medium (Life technologies, NY, USA) supplemented with Cell-Ess® serum
replacement (Essential pharmaceuticals LLC, NJ, USA) and 5 mM L-glutamine (Life
Technologies, NY, USA). A 1 M glucose stock solution was prepared by mixing
anhydrous dextrose (EMD Millipore, MA, USA) in Millipore water and was filter
sterilized using 0.2 μm Fisherbrand™ syringe filters. The glucose stock solution was used
to adjust the initial glucose concentration to 10mM or 30 mM glucose in the 80:20
DMEM:CD CHO media mixture. rCHO DP-12 cells were preconditioned to the initial
glucose concentration for at least three passages prior to the experiment. Cells were
seeded at approximately 2 X 105 cells/mL in 75 cm2 flasks (Corning Inc, NY, USA) and
incubated at 37°C in humidified 5% CO2 and shaken at 120 rpm. Anti-clumping agent
(Life technologies, NY, USA) was added (1:250) to the medium prevent cell clumping.
Cell concentration and viabilities, glucose and lactate concentrations were obtained every
12 hours. Cell concentrations and viabilities were measured using Bio-Rad TC20™
Automated Cell Counter (Bio-Rad Laboratories, CA, USA). Glucose and lactate
concentrations were obtained using a Yellow Springs Instruments (YSI) 2900
Biochemistry Analyzer (Yellow Springs, OH, USA). All conditions were conducted in
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duplicates. Statistical analysis on the growth rates of different conditions were performed
using JMP (SAS Institute, NC, USA).

5.3.2 RNA Isolation
For transcriptome analysis, RNA samples were extracted 36 hours after
inoculating the cells, while the cells were in mid-exponential growth phase. To collect
mRNA samples, RNAprotect® cell reagent (Qiagen, Valecia, CA) was added to a
harvested sample immediately upon withdrawal from the flask. Total RNA extraction
was performed as per RNeasy Plus Mini kit (Qiagen) protocol. Total RNA was extracted
into 1.5 mL RNAase-Free, DNAase-Free tubes and stored in -80°C until required. A
NanoDrop 8000 UV-Vis spectrophotometer (Thermo Scientific, MA, USA) and Agilent
2100 Bioanalyzer System (Agilent, Santa Clara, CA) with RNA 6000 Nano kit (Aglient)
were used to confirm the quality of the extracted total RNA samples. All samples had
RNA integrity numbers (RIN) values of greater than nine.

5.3.3 Library Synthesis, Sequencing and Reference Mapping
The cDNA libraries for whole transcriptome sequencing for each sample were
constructed by following the recommended protocol of the TruSeq RNA sample
preparation v2.0 kit (Illumina, San Diego, CA). Briefly, messenger RNA (mRNA) was
enriched from total RNA using poly-T magnetic beads. Next, mRNA was cleaved into
fragments by a non-specfic RNA endonuclease and the fragmentation products were
synthesized into complementary DNA (cDNA) using reverse transcriptase and DNA
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polymerase enzymes, respectively. The cDNA products then underwent end repair
process to flush, A-tail, and phosphorylate the DNA ends. These products were ligated to
adapters that serve as priming sites for enrichment by PCR to create the cDNA libraries
for sequencing. Each library contains an individual specific DNA index that is used for
multiplexing during massively parallel sequencing. The resulting cDNA libraries were
quality validated on an Agilent 2100 Bioanalyzer System to ensure proper fragment
distribution (~260 bp) and effective removal of adapter dimers. Sequence libraries were
multiplexed and sequence data collected on 2 lanes of a HiSeq 2500 (Illumina, San
Diego, CA) at the Genomics division of David H. Murdock Research Institute
(Kannapolis, NC) using a 2×101 bp, paired end read type. Raw sequence reads were
demultiplexed on the instrument and reads greater than or equal to 36 bp were cleaned of
adapter and low quality bases (less than Phred 15) with the Trimmomatic software
package (Bolger, et al. 2014).
The trimmed reads obtained were mapped on to the Chinese hamster reference
genome sequence (RefSeq AMDS00000000, AMDS01000000) with the Subread Aligner
(v1.4.5) (Liao, et al. 2013b). Subread performed local alignment of the reads and reported
the locations that have the largest overlap among the reads. FeatureCounts was used to
assign the reads to the target genes and summarize the data into a read counts table(Liao,
et al. 2013a). This table was subsequently used as input in the differential gene
expression analysis.

5.3.4 Differential Gene Expression Analysis and Gene Ontology Analysis
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Differential gene expression analysis of the RNA-Seq data used the edgeR
software package for data filtering and statistical analysis (Robinson et al., 2010). edgeR
utilizes a negative binomial distribution model to capture the quadratic mean-variance
relationship common to RNA-Seq data (Robinson and smyth 2007, Chen 2014, Robinson
and smyth 2008). Additionally, edgeR employs an empirical Bayes method to stabilize
over-dispersion across genes by sharing information across all observations including
replicates (Robinson 2010, Fong 2012, McCarthy 2012). The steps used for RNA-Seq
statistical analysis were a) filtering low expressed genes, b) normalizing the library sizes,
c) visualizing the multidimensional scaling plots, d) estimating dispersions across genes,
e) conducting exact tests to identify differentially expressed genes and f) performing the
overrepresentation analysis using GOseq. For filtering the low expressed genes, a gene
was retained for statistical analysis if the count-per-million (cpm) value was greater than
1.0 in at least two samples (Anders 2013). To normalize the library sizes, all of the
samples were normalized using the trimmed mean of M-values (TMM) method in edgeR
(Robinson and Oshlack 2010). A multidimensional scaling (MDS) algorithm in edgeR
was used to visualize the similarities and dissimilarities between the samples (Appendix
B.4) (Robinson and Oshlack 2010). Tagwise dispersions were estimated for the design
matrix using the quantile-adjusted conditional maximum likelihood (qCML) method
(McCarthy 2012). Genes with differential expression due to the glucose concentration
were identified using an exact test, similar to fisher’s exact test (Robinson and smyth
2008). P-values were adjusted to control the false discovery rate by a BenjaminiHochberg procedure and genes with FDR ≤ 0.01 were deemed as statistically significant,
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unless otherwise specified (Benjamini 2001). Gene ontology enrichment analysis was
performed using goseq software – a R based Bioconductor package (Young, et al. 2012).
GOseq accounts for selection bias for long and overexpressed gene sequences by
calculating the Probability Weighting Function (PWF) (Oshlack and wakefield 2009).
For GO analysis, goseq uses two vectors – one containing all the measured genes and the
other containing the differentially expressed genes. Additional information containing
genes length and the GO categories associated with the genes were supplied. GO terms
with p ≤ 0.05 from the over-representation test were considered to be statistically
significant. Additionally, manual screening of gene and gene families, that had common
stem in its gene symbol, with greater than 1.5-fold expression change was performed to
identify genes sensitive to serum-free medium adaptation process.
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5.4 Results and Discussion
The rCHO DP-12 cells were seeded into the media containing high and low initial
glucose concentrations in T-75 flasks at ~ 2 X 105 cells/ mL to allow cultures to grow
exponentially and to have minimal lactate buildup. It was desired to have a chemically
defined, serum-free, animal-free, protein-free medium for this study; however it was too
expensive for such a small experiment to have a custom CD CHO medium formulated
with low glucose. So an alternative was designed based on DMEM medium with a serum
replacement supplemented with 20% CD CHO medium, in order to reduce adaptation
timelines. The cell, glucose, and lactate concentration profiles for the two conditions are
shown in Figure 5.1.
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Figure 5.1: Cell concentration (A), glucose (circles) and lactate profiles (squares) are
shown for CHO cells cultured under high glucose (closed symbol) and low glucose (open
symbol) conditions. Black arrows indicate time of RNA harvest.
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As expected, the specific growth rates were not significantly different (P < 0.05)
for the cultures with initial concentrations of 10 mM and 30 mM glucose over the first 36
hours, while both cultures had above 2 mM glucose (Li et al.). To characterize the impact
of the initial glucose concentration on the transcriptome of CHO cells transcriptome,
RNA was extracted from parallel cultures in mid-exponential phase where glucose
concentration was the only major difference between the cultures. Specifically, one set of
cultures had started at 30 mM glucose and had reached 23.4 ± 0.9 mM glucose and the
other set of cultures had started at 10 mM glucose and reached 4.9 ± 0.1 mM glucose.
Additionally, the lactate concentrations were 12.2 ± 0.3 mM and 11.6 ± 0.4 mM for high
and low glucose conditions respectively and were not statistically different (P < 0.05).
Correspondingly, the glucose consumption rates and lactate production rates were at 36hour time point were not different. In contrast, after 36-hours, when the glucose
concentration in the low glucose cultures dropped below 5 mM glucose, the glucose
consumption rates and lactate production rates were different, as expected (P < 0.05).

5.4.1 RNA-Seq analysis of glucose concentrations on CHO cell transcriptome
RNA-Seq data obtained from HiSeq 2500 was assembled and aligned with the aid
of Chinese hamster reference genome (Lewis et al. 2013). Overall, 27,629 genes mapped
to the Chinese hamster genome. Differential gene expression analysis was carried as per
the procedure detailed in materials and methods. Of the 27,629 genes, only 10,090 genes
were expressed based on the filtering criteria used. An exact test was performed on the
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10,090 genes to identify which genes had differential expression due to glucose
concentrations, and only 575 genes were identified as significantly different (FDR ≤
0.01). Of the 575 genes identified as sensitive to the glucose concentration, around 60%
of the genes had lower expression in CHO cells cultured in low glucose medium. Of the
575 genes, 116 of these genes (~20%) had gene symbols beginning with ‘LOC’ genes,
meaning that the functional characteristics of these genes are uncertain. It should be noted
that only 216 genes had 1.5-fold or greater difference in expression level between the two
culture conditions. Furthermore, 283 genes of the 575 significant genes had gene
ontology terms associated with it. Gene ontology (GO) enrichment analysis using GOseq
biconductor package was used to identify biological processes that are over-represented
among the significant genes. The enriched GO terms with five or more genes in its
category are shown in Table 5.1. Genes related to immune response, oxidation-reduction
process and protein transport were enriched among the glucose sensitive genes. The
immune response GO term was represented by chemokines (Tnfsf9 and Cxcl3) that
induce proliferation and attract neutrophils, cytokines (Lif) and genes with antiviral
activity. The exact mechanisms through which these genes are related to external glucose
concentrations need to be further evaluated. Oxidation-reduction process had 12 genes
enriched among the glucose sensitive genes. The oxidation-reduction genes had an
overall trend of decrease in expression, as 9 out of the 12 genes had lower expression in
rCHO DP-12 cells cultivated at low glucose medium. These genes belonged to several
different families involved in oxidation-reduction reactions such as reductase, oxygenase
and dehydrogenase. One possible explanation for the trend of these genes could be that
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the cells under low glucose concentration experienced low/no oxidative stress. Several
studies have documented the induction of oxidative stress in response to high glucose
exposure (Chang, et al. 2003; Giugliano, et al. 1996; King and Loeken 2004). The
decrease in expression of oxido-reductase genes in CHO cells grown in low glucose
medium could possibly indicate that the oxidative stress might be lower with lower
glucose concentration. The reduced oxidative stress could be beneficial to the cells as
oxidative stress results in the production of reactive oxygen species that cause damages to
the cell including DNA damage. The protein transport GO term was represented by nine
genes, eight of which had decrease in expression in rCHO DP-12 cells in lower glucose
medium. Moreover, of the 9 genes, only 3 genes had over 1.5-fold change in expression.
Several of the genes belonged to RAS oncogene family or were related to it. Specifically,
several of these genes are involved in the regulation of intracellular transport and
formation of transport vesicles, mainly between ER and trans-Golgi network (Stenmark
and Olkkonen 2001). Rab14, along with other RAS oncogene genes, has been implicated
in regulating different steps of GLUT sorting (Leto and Saltiel 2012). However, the
relationship between the protein transport genes and external glucose concentration could
not be effectively understood and needs to be further investigated.
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Figure 5.2: Distribution of significant glucose sensitive genes in rCHO DP-12. About
two-thirds of the genes had known functions and a third of the genes were not
functionally annotated.
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Table 5.1 - Enriched significant genes in CHO cells cultured in low glucose medium (FDR ≤ 0.01)
Gene
Symbol

Gene Description

Foldchange

GO Terms Associated

Chemokine (C-X-C Motif) Ligand 3

1.3

Luekimia inhibitory factor

-1.3

2'-5'-oligoadenylate synthetase-like

-2.6

tubulointerstitial nephritis antigen-like
1, transcript variant X2

-2.3

GO:0005576, GO:0005125,
GO:0008009, GO:0006955
GO:0005576, GO:0005125,
GO:0006955
GO:0003723, GO:0005524,
GO:0016740, GO:0006955
GO:0005044, GO:0008234,
GO:0030247, GO:0006508,
GO:0006955
GO:0016020, GO:0005164,
GO:0006955

immune response (GO:0006955)
Cxcl3
Lif
Oasl
Tinagl1

Tnfsf9

tumor necrosis factor (ligand)
superfamily, member 9
oxidation-reduction process (GO:0055114)
Acad9
Adh7

Akr1e2
Cbr3

Fmo4
Hmox1
Idh3b
Kcnab2

Leprel1

1.3

acyl-CoA dehydrogenase family,
member 9
alcohol dehydrogenase 7 (class IV),
mu or sigma polypeptide, transcript
variant X2
aldo-keto reductase family 1, member
E2, transcript variant X1
Carbonyl Reductase 3

flavin containing monooxygenase 4,
transcript variant X1
heme oxygenase (decycling) 1,
transcript variant X2
isocitrate dehydrogenase 3 (NAD+)
beta, transcript variant X1
potassium voltage-gated channel,
shaker-related subfamily, beta member
2, transcript variant X3
leprecan-like 1, transcript variant X2

1.3
-2.5

-1.5
-1.4

-1.5
-1.3
-1.4
1.7

-1.6

Ptgr1

prostaglandin reductase 1, transcript
variant X2

-1.5

Ptgs2

prostaglandin-endoperoxide synthase
2 (prostaglandin G/H synthase and
cyclooxygenase), transcript variant X3

-1.6
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GO:0003995, GO:0016627,
GO:0008152, GO:0055114
GO:0003824, GO:0005488,
GO:0008270, GO:0016491,
GO:0008152, GO:0055114
GO:0016491, GO:0055114
GO:0003824, GO:0005488,
GO:0016491, GO:0008152,
GO:0055114, GO:0003824,
GO:0005488, GO:0016491,
GO:0008152
GO:0004499, GO:0050660,
GO:0050661, GO:0055114
GO:0004392, GO:0006788,
GO:0055114
GO:0000287, GO:0016616,
GO:0051287, GO:0055114
GO:0016491, GO:0055114

GO:0005506, GO:0016491,
GO:0016705, GO:0031418,
GO:0055114
GO:0003824, GO:0005488,
GO:0008270, GO:0016491,
GO:0008152, GO:0055114
GO:0004601, GO:0020037,
GO:0006979, GO:0055114

Table 5.1 - Enriched significant genes in CHO cells cultured in low glucose medium (FDR ≤
0.01)
Xdh

xanthine dehydrogenase, transcript
variant X2

1.4

GO:0003824, GO:0009055,
GO:0016491, GO:0046872,
GO:0050660, GO:0051536,
GO:0055114

-1.2

GO:0015031

-1.7

GO:0005622, GO:0016020,
GO:0003924, GO:0005525,
GO:0007165, GO:0007264,
GO:0015031
GO:0016020, GO:0043231,
GO:0008324, GO:0006812,
GO:0015031, GO:0055085
GO:0005622, GO:0003924,
GO:0005515, GO:0005525,
GO:0006886, GO:0006913,
GO:0007165, GO:0007264,
GO:0015031
GO:0005622, GO:0003924,
GO:0005515, GO:0005525,
GO:0006886, GO:0006913,
GO:0007165, GO:0007264,
GO:0015031
GO:0005622, GO:0003924,
GO:0005515, GO:0005525,
GO:0006886, GO:0006913,
GO:0007165, GO:0007264,
GO:0015031
GO:0005622, GO:0003924,
GO:0005515, GO:0005525,
GO:0006886, GO:0006913,
GO:0007165, GO:0007264,
GO:0015031
GO:0005622, GO:0005525,
GO:0007264, GO:0015031
GO:0005622, GO:0005525,
GO:0007264, GO:0015031

protein transport (GO:0015031)
Chmp7
Gem

Rab11fip5

charged multivesicular body protein 7,
transcript variant X2
GTP binding protein overexpressed in
skeletal muscle, transcript variant X2

RAB11 family interacting protein 5
(class I), transcript variant X2

-1.5

Rab14

RAB14, member RAS oncogene
family, transcript variant X2

1.3

Rab34

RAB34, member RAS oncogene
family, transcript variant X3

-1.3

Rab43

RAB43, member RAS oncogene
family, transcript variant X2

-1.3

Rab7b

RAB7B, member RAS oncogene
family, transcript variant X2

-1.4

Rhob

ras homolog family member B,
transcript variant X2
ras homolog family member Q,
transcript variant X2

-1.4

Rhoq

-1.5
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Since the GO enrichment analysis was not entirely effective in understanding the
impact of glucose concentrations on CHO cell transcriptome, top 10 genes with the
highest and lowest fold-changes were manually screened and further investigated (Table
5.2). Of the 20 genes, 8 genes were LOC genes i.e. were not functionally annotated.
Among the remaining genes, none of the genes had functions that were directly related to
glucose metabolism. Hence a more concentrated approach was taken and the glucose
sensitive genes were compared to glycolysis and TCA cycle genes. Additionally, the
glycosylation related genes were also compared to the glucose sensitive genes.
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Table 5.2: Top glucose sensitive genes with highest and the lowest fold-changes
Gene symbol

Gene Description

Foldchange

Higher Expression
Abcb1b
ATP-Binding Cassettem Sub-family B, Member
1
Apobr
apolipoprotein B receptor
Cd82
CD82 molecule, transcript variant X2
Gdpd4
glycerophosphodiester phosphodiesterase
domain containing 4
Gk
glycerol kinase, transcript variant X1
LOC100773612 ribosomal protein S6 kinase alpha-2, transcript
variant X3
LOC103159228 uncharacterized LOC103159228
LOC103160604 uncharacterized LOC103160604
LOC103161223 uncharacterized LOC103161223, transcript
variant X4
Trpm8
transient receptor potential cation channel,
subfamily M, member 8, transcript variant X3
Lower Expression
Ckb
creatine kinase, brain, transcript variant X2
Col12a1
collagen, type XII, alpha 1, transcript variant X3
Ctgf
connective tissue growth factor
Dsp
desmoplakin, transcript variant X2
Epha2
EPH receptor A2, transcript variant X2
LOC100754646 small proline-rich protein 2H, transcript variant
X2
LOC100766854 cytochrome P450 4X1
LOC100769145 liver carboxylesterase 4-like, transcript variant
X1
LOC103163538 uncharacterized LOC103163538, transcript
variant X2
Mmp12
matrix metallopeptidase 12 (macrophage
elastase), transcript variant X2
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2.0
2.2
2.0
6.2
2.4
2.3
2.1
2.0
2.2
1.9

-3.8
-3.1
-5.4
-3.3
-3.0
-4.3
-3.5
-5.1
-3.5
-3.0

5.4.2 Glycolysis and TCA cycle Genes
Glucose is the major carbon and energy source for CHO cells, where glucose is
processed to energy and metabolic precursors via the glycolysis and tricarboxylic acid
(TCA) cycle. It would be expected that extracellular glucose concentrations might affect
the transcription of glycolysis and TCA cycle genes. There are about 81 genes that code
for key enzymes and transport proteins related to glycolysis and TCA cycle. Of the 81
genes, 30 genes were filtered out as lowly expressed genes; however most of these genes
were variants of the major isoforms expressed. Only two glycolysis genes (Pfkfb3 and
Pgm1) and two TCA cycle genes (Idh3b and Suclg2) had significantly different levels
between the high and low glucose cultures (FDR ≤ 0.01) (Table 5.3). When the criterion
was relaxed to FDR ≤ 0.05, two additional genes passed the cutoff; one glycolysis gene
(Tpi1) and one TCA cycle gene (Pc) (Table 5.3). Among the six significantly glucose
sensitive genes (FDR ≤ 0.05) belonging to glycolysis and TCA cycle, no gene had greater
than 1.5-fold change in expression. However, it was interesting to see a decrease in
expression of Pfkfb3 gene. Pfkfb3 encodes for 6-phosphofructo-2-kinase/fructose-2,6biphosphatase 3, a bi-functional enzyme that has kinase activity as well as biphosphatase
activity directed towards the synthesis and degradation of fructose-2,6-bisphosphate. The
enzyme, Pfkfb3, acts as a feedback regulator of glycolysis through its inhibition by
phosphoenol pyruvate (PEP), a downstream intermediate in glycolysis. Elevated Pfkfb3
expression has been associated with high glycolytic flux in several tumor cells and
rapidly proliferating cells. In contrast, reduced levels of Pfkfb3 in mice models have
observed reduction in glycolysis and more controlled uptake of glucose (Mor, et al.
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2011). The decrease in expression of Pfkfb3 in CHO cells exposed to low glucose
medium could result in more controlled glycolysis in CHO cells. However, further
studies are required to correlate the impact of gene expression at a proteomic or a
metabolic level. Overall, there were no major changes between the genes involved in
glycolysis and TCA cycle. This could imply that glucose concentrations do not simply
control metabolic pathways at gene or DNA level.
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Table 5.3: Glycolysis and TCA cycle gene expression in rCHO DP-12 cultured in low
glucose relative to the high glucose medium
Gene symbol
Glycolysis
Pfkfb3
Pgm1
Tpi1 (FDR ≤
0.05)

Fold
change

Gene Description
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3,
transcript variant X4
phosphoglucomutase 1, transcript variant X2

-1.3
-1.3

Triosephosphate Isomerase 1

-1.2

isocitrate dehydrogenase 3 (NAD+) beta, transcript
variant X1

-1.4

TCA cycle
Idh3b
Pc (FDR ≤
0.05)
Suclg2

Pyruvate carboxylase
succinate-CoA ligase, GDP-forming, beta subunit,
transcript variant X2
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1.3
1.3

5.4.3 Glycosylation
Glycosylation is one of the critical post-translational modifications involving the
addition of carbohydrate moieties on the nascent protein inside the Golgi apparatus.
Glycosylation of therapeutic proteins is critical in determining the efficacy,
immunogenicity and stability of the protein (Walsh and Jefferis 2006). In industries,
obtaining consistent glycosylation profiles is necessary for regulatory approval. Fan et al.
(2013) noticed that the balance of glucose and amino acid metabolism is crucial for
glycosylation of recombinant proteins. In this study, the impact of initial glucose
concentration on glycosylation was investigated by observing the gene expression levels
of 266 glycosylation-related genes, previously identified by Xu et al. (2011). When the
glycosylation genes were compared to the 575 genes that were sensitive to the initial
glucose concentration in the medium (FDR ≤ 0.01), only six genes had significantly
differential expression between the high and low glucose cultures (Table 5.4). Of the six
genes, two genes had more than 1.5-fold change in expression – UDP-glucose
glycoprotein glucosyltransferase 2 Uggt2 and mannosidase alpha (Man1c1) expression.
UGGT2 gene encodes for a protein of the ER quality control machinery that is
capable of sensing incomplete folding of glycoproteins. Specifically, UGGT2 protein
attaches a single glucose residue to the incompletely folded or the misfolded glycan. This
enables the misfolded proteins to rebind with calnexin and re-enter the protein folding
cycle (Dejgaard, et al. 2004). The increased expression of UGGT2 in CHO cells cultured
in low glucose medium could be beneficial in guiding correct protein folding of the
recombinant proteins through the ER machinery. In particular, this can reduce the
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occurrence of protein aggregates due to improper protein folding, thereby improving
product quality Man1c1 is one of the members of alpha mannosidases family that are
involved in the trimming of mannoses from N-linked glycosylation inside golgi. The
lower expression of mannosidases could potentially impact the proportion of high
mannose structures, which has been known to elicit rapid removal of the therapeutic
protein from circulation system. However, the other major members of the mannosidases
family such as Man1a1 and Man1a2 were not significantly impacted by the external
glucose concentrations. As glycosylation is very important in recombinant protein
production, no major gene changes related to glycosylation due to glucose concentrations
would mean that glucose levels could be controlled to lower levels without affecting
glycosylation appreciably. In fact, the increased expression of UGGT2 gene could
potentially improve the product quality through correct protein folding.
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Table 5.4: Protein glycosylation genes that were sensitive to external glucose
concentration.
Gene
Symbol
Fuca1
Uggt2
Ext1
Man1c1
Neu1
St3gal1

Gene Family
Fucosidases
Glucosyltransferases
HS GlcNAc/GlcA Transferase
Mannosidase
Sialidases
Sialyltransferases
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Fold Change
1.4
1.5
-1.4
-1.7
-1.4
-1.4

5.5 Conclusions
Standard cell culture medium has high glucose concentrations (30mM), which
does adversely affect productivity due to waste product accumulation. These gene
expression studies demonstrate that no notable glycolysis, TCA or glycosylation gene
expression changes were observed in CHO cell culture in medium initially containing 30
mM and 10 mM glucose, yet the potential to reduce lactate accumulation is improved
with a low initial glucose concentration. Additionally, the ability to have CHO cell enter
a lactate consumption phase is improved with a lower initial glucose concentration (Luo,
et al. 2012; Mulukutla, et al. 2012; Zagari, et al. 2013). These expression studies
indicated that low glucose concentration batch medium for fed-batch CHO cell cultures
has potential to improve processes by reducing waste accumulation without impacting
process related genes.
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CHAPTER SIX
CONCLUSIONS AND FUTURE WORK
In this dissertation work, next-generation transcriptomic technique, RNA-seq, was
used to characterize the transcriptome of CHO cells under relevant industrial conditions.
In Chapter 3, the serum-free medium adaptation process of CHO cells was characterized
to identify critical genes and gene families that are necessary for successful adaptation.
For example, it was noticed that the gene expression of several antioxidant genes were
affected in both CHO cells during the adaptation process, indicating that the cells were
under oxidative stress. In chapter 4, the transcriptome of rCHO DP-12 and CHO DHFRcultivated under low temperature conditions was elucidated. Several key temperature
sensitive genes related to protein transport, DNA replication, cell cycle and glycosylation
genes were identified. In Chapter 5, the gene expression differences in rCHO DP-12 cells
exposed to two different glucose concentrations were quantified. The analysis identified
minimal differences in gene expression, especially related to glucose metabolism and
glycosylation, between the two conditions. Overall, the dissertation work provided a
transcriptome level-understand of CHO cells and identified several critical biomarkers
related to each industrially related condition studies. Future work should be conducted in
integrating the vast amounts of gene expression data obtained through this dissertation
work with metabolomic and proteomic-based data in order to obtain complete system
level understand of these industrially relevant conditions.
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Appendix A
Filtering of RNA-seq raw counts
In the differential gene expression analysis of RNA-seq data, an initial
independent filtering is performed to remove genes with low or no counts. Usually a
minimum cut-off value of 1 count per million (CPM) is used. However, the 1 cpm criteria
did not adequately filter the lowly expressed genes, as several of the low expressed genes
would appear as differentially expressed genes. In this study, we compared the filter
cutoff of 5 CPM and 10 CPM with 1 CPM to identify the best cut-off criteria to filter the
low count genes. Specifically, the impact of independent filtering on the results of
differential gene expression analysis was investigated. The statistical pairwise
comparison of rCHO DP-12 cultured at 33°C to rCHO DP-12 cells at 37°C was used as
the case study. The use of CPM 5 as the cutoff resulted in 12,163 genes post-filtering and
CPM 10 resulted in 11,016 genes post filtering, as opposed to 14,643 genes available
post-filtering for CPM 1. The ‘expressed’ genes were then used for differential gene
expression analysis. BCV plots were initially used to visualize the differences between
the 3 CPM cutoffs (Figure A1). From the figures, it can be clearly seen that the genes
with low counts had high variation and were effectively removed at higher CPMs (CPM
5 and CPM 10). Next, the genes that were differentially expressed (> 1.5-fold change) in
rCHO DP-12 cultured at low temperature for each CPM criteria was used in a Venn
diagram to see the common genes (FDR ≤ 0.01). Over 65% of the genes were common
between the three different filtering criteria used (Figure A2). The genes that were not
common were genes with FDR values close to 0.01 and hence depending on the
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comparison were either differentially expressed or were just outside the 0.01 FDR cutoff.
Additionally, the change in number of differentially expressed genes was also compared
between the different CPM cutoffs used. When GO enrichment analysis was performed
on the three different sets, most of the GO terms overlapped between the three cutoffs,
indicating that the results did not change drastically while using higher CPMs cutoff’s
(Figure A.3). Hence, the CPM 10 was chosen as the criteria for independent filtering of
low expressed genes.
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Figure A1: Biological coefficient of variation (BCV) plots for CPM 1, 5, 10 (top to
bottom) are an effective way to visualize the relationship of variance with expression
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Figure A2: Venn diagram of differentially expressed genes in rCHO DP-12 at 33°C
relative to 37°C with more than 1.5-fold cutoff between the three different CPM cutoff.
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Figure A.3: Venn diagram of enriched GO terms in rCHO DP-12 cultured at low
temperature at CPM 1, CPM 5, and CPM 10.
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APPENDIX B
MDS PLOTS

Figure B.1: MDS plots representing gene expression profiles of rCHO DP-12 (closed)
and CHO DHFR- (open) cultured at three different serum concentrations – 10%
(sqaures), 5% serum (circles) and 0% serum (triangles).
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Figure B.2: MDS plots representing gene expression profiles of rCHO DP-12 (Squares
and circles) and CHO K1-PF (triangles and diamonds) cultured at 37°C (circles and
diamonds, respectively) and 33°C (squares and triangles, respectively) and at pH 6.90
(closed) and pH 6.70 (open).

151

Figure B.3: MDS plot for gene expression profiles of rCHO DP-12 (closed) and CHO
K1-PF (open) at 37°C (circles) and 33°C (squares).
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Figure B.4: MDS plot for gene expression profiles of rCHO DP-12 cells in high glucose
(open) and low glucose (closed) medium.
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APPENDIX C
CORRECTED GLYCOYLSATION GENE LIST
Table C-1: Corrected Glycosylation gene list
Gene Symbol
A4GALT
A4GNT
AGA
ALG1
ALG11
ALG12
ALG13
ALG14
ALG2
ALG3
ALG5
ALG6
ALG8
ALG9
ARSA
ARSB
ARSE
B3GALNT1
B3GALNT2
B3GALT1
B3GALT2
B3GALT4
B3GALT5
B3GALT6
B3GAT1
B3GAT2
B3GAT3
B3GNT1
B3GNT2
B3GNT3
B3GNT4
B3GNT5
B3GNT7
B3GNT8

Gene Family
Galactosyltransferases
GlcNAc-transferases
Lysosomal Enzymes
Glucosyltransferases
Mannosyltransferases
Mannosyltransferases
Glucosyltransferases
Glucosyltransferases
Mannosyltransferases
Mannosyltransferases
Glucosyltransferases
Glucosyltransferases
Glucosyltransferases
Mannosyltransferases
Arylsulfatases
Arylsulfatases
Arylsulfatases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
UDP-glucuronosyltransferases
UDP-glucuronosyltransferases
UDP-glucuronosyltransferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
Galactosyltransferases
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Table C-1: Corrected Glycosylation gene list
B4GALNT1
B4GALNT2
B4GALNT3
B4GALNT4
B4galt1
B4GALT2
B4GALT3
B4GALT4
B4GALT5
B4GALT6
B4GALT7
C1GALT1
C1GALT1C1
CHPF
CHST1
CHST10
CHST11
CHST12
CHST13
CHST14
Chst15
CHST2
CHST3
CHST4
CHST7
CHST9
CHSY1
CMAS
CSGALNACT1
Csgalnact2
CTBS
CTSA
DAD1
DDOST
DPAGT1
DPM1
DPM3
DSEL

GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Galactosyltransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
GalNAc-transferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Galactosyltransferases
Nucleotide Synthesis
GalNAc-transferases
GalNAc-transferases
Lysosomal Enzymes
Lysosomal Enzymes
N-glycans-transferase
N-glycans-transferase
GlcNAc-transferases
Mannosyltransferases
Mannosyltransferases
Sulfotransferases
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Table C-1: Corrected Glycosylation gene list
EXT1
EXT2
EXTL1
EXTL2
EXTL3
FPGT
FUCA1
FUT1
FUT10
FUT11
FUT2
FUT4
FUT6A
FUT6B
FUT7
FUT8
FUT9
GAA
GAL3ST1
GAL3ST2
Gal3ST3
GAL3ST4
GALC
GALK1
GALK2
GALNS
GALNT1
GALNT11
GALNT12
GALNT13
GALNT14
GALNT15
GALNT16
GALNT18
GALNT2
GALNT3
GALNT5
GALNT6

HS GlcNAc/GlcA Transferase
HS GlcNAc/GlcA Transferase
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
Nucleotide Synthesis
Fucosidases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Fucosyltransferases
Hyaluronoglucosaminidases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Lysosomal Enzymes
Nucleotide Synthesis
Nucleotide Synthesis
Sulfatases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
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Table C-1: Corrected Glycosylation gene list
GALNT7
GALNT8
GALNT9
GALT
GBA
GBGT1
GCNT1
GCNT3
GCNT4
GFPT2
GLA
GLB1
GLCE
GM2A
GMDS
GMPPA
GMPPB
GNB1
GNB2L1
GNE
GNPDA1
GNPNAT1
GNS
GPI
GUSB
GYLTL1B
HAS2
HAS3
HEXA
HK1
HK3
HPSE
HPSE2
HS2ST1
HS3ST1
HS3ST2
HS3ST4
HS3ST5

GalNAc-transferases
GalNAc-transferases
GalNAc-transferases
Nucleotide Synthesis
Lysosomal Enzymes
GalNAc-transferases
#N/A
GlcNAc-transferases
GlcNAc-transferases
Nucleotide Synthesis
Galactosidase
Galactosidase
Miscellaneous
Lysosomal Enzymes
Nucleotide Synthesis
Nucleotide Synthesis
Nucleotide Synthesis
Nucleotide Synthesis
Nucleotide Synthesis
Nucleotide Synthesis
Nucleotide Synthesis
Nucleotide Synthesis
Sulfatases
Nucleotide Synthesis
Galactosidase
GlcNAc-transferases
Hyaluronan synthase
Hyaluronan synthase
Hexosaminidases
Nucleotide Synthesis
Nucleotide Synthesis
Heparanases
Heparanases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
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Table C-1: Corrected Glycosylation gene list
HS3ST6
HS6ST1
HS6ST2
HS6ST3
HYAL1
HYAL2
HYAL3
HYAL4
IDS
IDUA
KHK
LARGE
LCT
LFNG
LIPA
MAN1A1
MAN1A2
MAN1C1
MAN2A1
MAN2A2
MAN2B1
MANBA
MFNG
MGAT1
MGAT2
MGAT3
MGAT4A
MGAT4B
MGAT5
MGAT5B
Mgea5
MPI
NAGA
NAGK
NAGLU
NANS
NDST1
NDST2

Sulfotransferases
Sulfotransferases
Sulfotransferases
Sulfotransferases
Hyaluronoglucosaminidases
Hyaluronoglucosaminidases
Hyaluronoglucosaminidases
Hyaluronoglucosaminidases
Sulfatases
Iduronidases
Nucleotide Synthesis
GlcNAc-transferases
Lysosomal Enzymes
GlcNAc-transferases
Lysosomal Enzymes
Mannosidase
Mannosidase
Mannosidase
Mannosidase
Mannosidase
Mannosidase
Mannosidase
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
Hyaluronoglucosaminidases
Nucleotide Synthesis
Lysosomal Enzymes
Nucleotide Synthesis
Mannosidases
Nucleotide Synthesis
Sulfotransferases
Sulfotransferases
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Table C-1: Corrected Glycosylation gene list
Neu1
Neu2
Neu3
Neu4
NPL
OGT
PAPSS1
PAPSS2
PGM1
PIGA
PIGC
PIGH
PIGM
PIGP
PMM2
POFUT1
POFUT2
POMGNT1
POMT1
POMT2
RENBP
RFNG
RPN1
RPN2
SGSH
SLC35A1
SLC35A2
SLC35A3
SLC35A4
SLC35A5
SLC35B1
SLC35B2
SLC35B3
SLC35B4
SLC35C1
SLC35C2
SLC35D1
SLC35D2

Sialidases
Sialidases
Sialidases
Sialidases
Mannosidases
GlcNAc-transferases
Nucleotide Synthesis
Nucleotide Synthesis
Nucleotide Synthesis
GlcNAc-transferases
GlcNAc-transferases
GlcNAc-transferases
Mannosyltransferases
GlcNAc-transferases
Nucleotide Synthesis
Fucosyltransferases
Fucosyltransferases
GlcNAc-transferases
Mannosyltransferases
Mannosyltransferases
Nucleotide Synthesis
GlcNAc-transferases
N-glycans-transferase
N-glycans-transferase
Sulfohydrolases
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
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Table C-1: Corrected Glycosylation gene list
SLC35D3
SLC35E1
SLC35E3
SLC35E4
SLC35F1
SLC35F2
SLC35F3
SLC35F4
SLC35F5
ST3Gal1
ST3Gal2
ST3Gal3
ST3Gal4
ST3Gal5
ST3Gal6
ST6Gal1
ST6Gal2
ST6GalNAc3
ST6GalNAc4
ST6GalNAc5
ST6GalNAc6
ST8SIA1
ST8SIA2
ST8SIA3
ST8SIA4
ST8SIA5
ST8SIA6
SULF1
SULF2
TSTA3
UAP1
UGCG
UGGT2
UGP2
UGT2A1
UST
UXS1
WBSCR17

Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Nuc. Sugars Transporters
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sialyltransferases
Sulfatases
Sulfatases
Nucleotide Synthesis
Nucleotide Synthesis
Glucosyltransferases
Glucosyltransferases
Nucleotide Synthesis
UDP-glucuronosyltransferases
Sulfotransferases
Nucleotide Synthesis
GalNAc-transferases
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Table C-1: Corrected Glycosylation gene list
XYLT1
XYLT2

Xylosyltransferases
Xylosyltransferases
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